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Phosphodiesterases (PDEs), enzymes that hydrolyze cyclic nucleotides, are important 
components of signal transduction pathways in eukaryotic cells. Second messenger 3’-5’-
cyclic adenosine monophosphate (cAMP) is hydrolyzed by specific PDEs. By controlling 
concentration levels of cAMP in cell, PDEs preserve favorable environment for successful 
transmission of the cAMP signal. Moreover, PDEs are activated by protein kinase A (PKA) 
in response to elevated cAMP concentration, which is a feature crucial for signal 
termination.  
PDE8A1 is a high-affinity cAMP-specific IBMX insensitive phosphodiesterase, an 
enzyme important for cAMP signaling. However, mostly due to a lack of specific inhibitor, 
its role has not been assessed in detail. This thesis reports cloning of PDE8A1, 
identification of its posttranslational modifications and subcellular localization, as well as 
an alternative approach to address PDE biology by the use of cyclase toxin from 
Bordetella pertussis.  
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Fosfodiesterázy sú dôležitou súčasťou signálnych dráh eukaryotických buniek. Druhý 
posol 3’-5’-cyklický adenozín monofosfát (cAMP) je hydrolyzovaný špecifickými 
fosfodiesterázami. Kontrolou hladiny cAMP v bunke fosfodiesterázy zabezpečujú vhodné 
prostredie pre prenos cAMP signálu. Navyše, ako odpoveď na zvýšenú hladinu cAMP, sú 
fosfodiesterázy aktivované proteín kinázou A (PKA), čo je vlastnosť dôležitá obzvlášť pre 
patričné ukončenie signálu. 
Fosfodiesteráza 8A (PDE8A1) je vysoko-afinitná cAMP-špecifcká fosfodiesteráza 
necitlivá k inhibícii pomocou IBMX. Je významný enzýmom pre cAMP signalizáciu, avšak 
najmä kvôli nedostupnosti PDE8A špecifického inhibítoru, jej úloha ešte nebola detailne 
preskúmaná ani docenená. Prezentovaná práca zahŕňa klonovanie PDE8A1, identifikáciu 
jej posttranslačných modifikácii, lokalizáciu na bunkovej úrovni ako aj alternatívny prístup 
ku skúmania fosfodiesteráz pomocou cyklázového toxínu z Bordetelly pertussis. 
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(m)AKAP (muscle-specific) A-kinase anchoring protein 
AC Adenylate cyclase 
Arnt aryl hydrocarbon receptor nuclear translocator protein 
ATCC American Type Culture Collection 
cAMP Cyclic adenosine monophosphate 
CD cluster of differentiation 
cGMP Cyclic guanosine monophosphate 
CHO cells Chinese hamster ovary cells 
CIAP Calf-intestinal alkaline phosphatase 
cNMP Cyclic nucleoside monophosphate 
CXCL12 chemokine (C-X-C motif) ligand 12 
Cya A adenylate cyclase toxin from Bordetella pertussis 
DAPI 4',6-diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
EPAC exchange proteins activated directly by cyclic AMP 
ERK kinase extracellular-signal-regulated kinase 
EtBr Ethidium bromide 
FACS Fluorescence-activated cell sorting 
FBS fetal bovine serum 
FRET Förster (Fluorescence) resonance energy transfer 
FSC Forward Scatter 
FSK forskolin 
GAF cGMP-specific phosphodiesterases, adenylyl cyclases 
and FhlA 
GPCR G protein coupled receptors 




IPTG Isopropyl β-D-1-thiogalactopyranoside 
LA DNA polymerase long and accurate DNA polymerase 
MEK5 MAP/ERK kinase 5 
MEKK MAP kinase kinase kinase 
nt nucleotide 
Oct octamer transcription factor 
ORF open reading frame 
PAK p21 activated kinases 
PAS domain Per, Arnt, Sim domain 
PBS Phosphate buffered saline 
PCR polymerase chain reaction 
PDE Phosphodiesterase 
PGE1 Prostaglandin E1 
RACK-1 receptor of activated kinase 1 
REC domain CheY-like phosphoacceptor (or receiver) domain 
SOC Super Optimal broth with Catabolite repression 
TAPAS-1 domain tryptophan anchoring phosphatidicacid selective-
binding domain 1 
TBE Tris/ Borate/ EDTA 
TNFα Tumor necrosis factor alpha 
TPB Tryptose Phosphate Broth 
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Compartmentalization of biological pathways and molecules in eukaryotic cells is a 
fascinating and widespread phenomenon. Both molecules and signals are likely confined 
to different compartments, thus allowing biological processes not to constrain or 
interfere with each other. However, despite enormous extend of the research, some 
aspects remain controversial or still not assessed. 
The thesis presented here extends the research previously conducted in our laboratory 
(Laboratory of cellular immunology) that identified PDE8A as membrane protein with 
potential localization to lipid rafts (Falteisek 2008). Previous studies performed by Lukáš 
Falteisek were focused only on N-terminal segments of the PDE8A protein and 
determination of their cellular localization. It was decided that characterization of 
PDE8A1 should include the study of the whole protein and its subcellular localization with 
regards to compartments of cAMP (production and utilization) and membrane micro-
domains (rafts). This decision shaped the main goals of this thesis. First objective was to 
prepare full-length fluorescently tagged PDE8A1. Second objective was to construct 
PDE8A1 variants that would carry mutations in signal sequence for N-myristoylation and 
palmitoylation and verify their cellular localization as was done for the N-terminal 
segments (Falteisek 2008).  
An interesting challenge was to design an experimental system, possibly in living cells, 
where the role of subcellular localization of PDE8A1 could be assessed. This goal included 
construction of catalytically inactive PDE8A1 that later would be part of control 
measurements within the suggested experimental system. 
PDE8A1 represents an interesting protein, quite divergent from other members of PDE 
family,  putatively essential for function of various tissues. However, in contrast to related 
PDE4 is only poorly studied. Aspiration of this thesis is to add a small piece of knowledge 
to fill this gap. More general, this thesis gives the preliminary data to the long-term fierce 
discussion about functional relevance of membrane microdomains establishing model 
system for testing interplay between two raft-localized proteins with opposite functions 
(cAMP production vs. utilization). 
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2 Review of available literature 
2.1 Phosphodiesterases (PDEs) 
Signaling by cyclic nucleotides is a complex process that requires fine tuning with 
regards to the specific physiological state of any particular cell (Conti and Beavo 2007, 
Serezani et al 2008). Since PDEs play important role in this widespread mechanism of 
cellular signalization, it is not surprising that they are subject to this tuning and that this is 
reflected by the abundance and structural variability of PDE genes and vice versa (Conti 
and Beavo 2007). 
2.1.1 Diversity of PDEs 
Already in the seventies there were first observations that phosphodiesterases are 
diverse in structure and enzymatic properties (Donnelly 1977). Later, during studies 
focused on the development of immunoprecipitation of calmodulin-phosphodiesterase 
complexes, different molecular sizes of the isoforms originating in heart or brain tissue 
were observed (Hansen and Beavo 1982). This observation subsequently led to discovery 
of another isoform of calmodulin dependent phosphodiesterase in brain tissue (Hansen 
and Beavo 1986) and formed the basic knowledge about group of PDEs that would later 
become the PDE1 gene family.  
Within years of research, many more genes and proteins were discovered resulting in 
11 gene families of mammalian PDEs and approximately a hundred of resulting proteins 
recognized today (Beavo 2007). 
 
2.1.2 Variability of PDEs in mammals 
In human genome, 21 PDE genes have been identified and divided into gene families 
according to their enzymatic properties and sequence similarity. . Gene families PDEs 1, 2, 
3, 10 and 11 lack substrate specificity and hydrolyze both cAMP as well as cGMP with 
varying efficiency. cGMP is specifically hydrolyzed by PDEs belonging to gene families 
PDEs 5, 6 and 9, while PDEs 4, 7 and 8 hydrolyze cAMP (Conti and Beavo 2007). PDE8 
gene family consists of PDEs that bind specifically cAMP, with high affinity, and are 
distinguished by their insensitivity to IBMX, a cAMP analogue that successfully inhibits 
other cAMP specific PDEs (Fisher et al 1998, Soderling et al 1998).  
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As mentioned above, the fine tuning of cyclic nucleoside signaling mechanisms 
requires large collection of PDEs with slightly modified localization, protein interactions 
and enzyme kinetics. In order to meet this requirements, genes coding PDEs are 
organized in modular fashion enabling numerous exons to be alternatively spliced and 
give rise to variety of PDEs (Conti and Beavo 2007). PDE4A gene is a good example of this 
phenomenon, since it contains multiple exons (approximately 15) separated by long 
stretches of non-coding DNA, that are joined in multiple variants of mRNA and resulting in 
7 proteins (Rena et al 2001, MacKenzie et al 2008, Uniprot database). PDE4D gene is also 
transcribed in at least 9 different mRNAs, to six of which corresponding protein was found 
in mammalian tissues (Richter et al 2005). For PDE9A there were 20 transcripts reported 
and similar pattern was observed in other PDE genes, although the numbers are not final, 
since more are to be discovered and some might prove to be protein non-coding 
transcripts (Conti and Beavo 2007).  
In order to differentiate expression of PDE isoforms mammalian PDE genes contain 
multiple promoters, what is well documented in the case of PDE4D where there are two 
verified promoters, one regulating the expression of isoforms PDE4D1/2 and another 
promoter for PDE4D5, yet still another two predicted promoters need to be confirmed (Le 
Jeune et al 2002, Vicini and Conti 1997). The extent of expression as well as tissue specific 
distribution is determined by isoform-specific promoter, in this way is for example 
achieved limited tissue distribution of PDE4A8 in brain, skeletal muscle and to lesser 
extent in testis, while another variant, PDE4A10, is present in variety of tissues such as 
hearth or small intestine (MacKenzie et al 2008, Rena et al 2001). Promoters of PDE genes 
are localized in introns just upstream of the first exon of the corresponding PDE variant 
and often lack TATA-box but contain stretches of high GC content and cAMP responsive 
elements. Their presence allows gene regulation of PDEs on transcription level in 
response to concentration of cellular cAMP (Le Jeune et al 2002, Vicini and Conti 1997). 
Presence of multiple promoters in PDE genes specific for particular isoforms corresponds 
well with their different tissue specific expression, however present knowledge does not 




2.1.3 Variable regions of PDEs 
In contrast to structure of catalytic domain, which is well conserved among PDEs, both 
N- and C- terminal regions are highly variable. Variability of N-terminal region is mostly 
responsible for an amazing diversity of PDE isoforms present within the organism as 
illustrated by Richter et al 2005 or reviewed by Conti and Beavo 2007. Such extensive 
diversity is out of scope of this thesis and will be assessed briefly, focusing rather on what 
is relevant to the main subject of this study (PDE8A and signaling through cAMP), thus 
PDEs with dual specificity or specificity to cGMP are on the periphery of interest.  
Although a phosphorylation site of ERK2 kinase was detected in PDE4D in the C-
terminal portion of the catalytic domain (MacKenzie et al 2000), only very limited 
information is available about the region of PDEs located behind catalytic domain (Conti 
and Beavo 2007). In contrast numerous regulatory and phosphorylation domains were 
localized to N-terminal portion of PDEs (Conti and Beavo 2007).  
Plethora of functional elements is present in the N-terminal region of PDEs. 
Dimerization is common among PDEs and although the functional role of oligomerization 
state of PDEs is not fully understood, regions responsible for dimerization has been 
mapped to N-terminal segment (Conti and Beavo 2007). However not all PDE genes are 
known to include oligomerization domains and some isoforms are known to lack this 
feature at all (Conti and Beavo 2007). In addition to dimerization domains variable regions 
of PDEs also contain regulatory elements such as ligand binding domains and 
phosphorylation sites. For example five of the 11 PDE families, PDE2, PDE5, PDE6, PDE10 
and PDE11, contain so called GAF domain that are able to allosterically regulate 
enzymatic activity or facilitate formation upon binding of cNMP (Conti and Beavo 2007). 
All PDE4 genes codes for conserved protein motif that represents phosphorylation site for 
PKA, however this motif is not included in all isoforms due to alternative splicing 
(MacKenzie et al 2002). 
Variability of N-terminal region of PDEs is thought to be connected to 
compartmentalization of cAMP signaling, where particular variant of N-terminus can 
facilitate the direct association of the concerned PDE with specific signaling circuit 
(Houslay et al 2007).  
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This targeting can be achieved by association with different cellular membranes, as it is 
in the case of PDE4A1, where TAPAS-1 domain facilitates phospholipid binding (Bailie et al 
2002). Fine tuning is further achieved by specific binding of TAPAS-1 domain to 
phosphatidic acid in calcium dependent manner, that could provide link to Ca2+ signaling, 
however once this association is established it is not easily abolished even after 
chelatation of Ca2+ ions. This molecular mechanism can serve as a sort of long term 
signaling “memory” of particular Ca2+ release event (Bailie et al 2002).  
Another way of implementing PDEs into specific circuits might be through association 
with scaffolding proteins such as A-kinase anchor protein (AKAP) or RACK-1 (Houslay et al 
2007). PDE4D3 is associated with muscle specific AKAP, but PDE4D5 is not, since the 
interaction is mediated by the N-terminal segment of PDE4D protein that actually 
distinguish PDE4D3 from PDE4D5 (Dodge et al 2001). Scaffold protein mAKAP thus brings 
to proximity PKA activated by elevated levels of cAMP and PDE4D3 capable of hydrolyzing 
cAMP. Moreover rate of cAMP hydrolysis by PDE4D3 can be altered if specific sites are 
phosphorylated, eventually by PKA, suggesting a possible negative feedback loop (Dodge 
et al 2001). Later, after more detailed examination, it was shown that mAKAP indeed 
forms a signaling module with incorporated negative feedback loop, where presence of 
PDE4D3 controls the duration of the signal, in the form of PKA activity (Dodge-Kafka et al 
2005). While PDE4D3 is associated with mAKAP, the PDE4D5 isoform binds to proteins 
RACK1 and β-arrestin, and again this interaction mediated by N-terminal segment which 
allows distinction between isoforms of PDE4D (Lynch et al 2005). Moreover detailed 
mapping of this interaction domain revealed that binding sites for RACK1 and β-arrestin 
overlaps in PDE4D5, so that the binding is mutually exclusive (Bolger et al 2006). Thus 
RACK1 and β-arrestin compete for binding to PDE4D5 and subsequently sequester it in 
distinct signaling circuits (Bolger et al 2006). 
2.1.4 The catalytic domain 
Based on the sequence and structure of catalytic domain, 3 classes of PDEs are 
distinguished (Conti and Beavo 2007, Richter 2002). Class III PDEs are related to purple 
acid phosphatases and thus considered to belong to a large family of 
dimetallophosphoesterases. They are to confined to the prokaryotes and their catalytic 
activity depends on presence of Fe2+ ions in the catalytic site (Richter 2002). PDEs with 
15 
 
class II catalytic domain are known from fungi, slime mold Dictyostelium discoideum  and 
bacteria (Conti and Beavo 2007). Detailed study of PDEs of D. discoideum suggests that 
they form two subgroups, one of which bears a resemblance to metallo-β-lactamases 
(Bader et al 2007). Most studied are class I PDEs that are present in fungi, protozoans and 
in metazoans they are the sole class of PDEs (Conti and Beavo 2007). Dealing with 
classification and distribution of PDEs in different organisms, it should be mentioned that 
there is not much known about PDEs in plants and although several genes possibly coding 
for PDEs has been identified, evidence is still lacking (Martinez-Atienza 2007). Known 
inhibitor of wide spectrum of animal PDEs, IBMX, hastens plant response to potential 
pathogen, suggesting important functional role of PDEs in plant physiology, however 
which genes and proteins are responsible for cAMP metabolism in plants remain unclear 
(Ma et al 2009). 
Mammalian PDEs are considered to be very good targets for pharmacological 
interventions and since rational drug design require knowledge of the structure, for many 
PDEs resolved 3D-proteins structure is available by now (Conti and Beavo 2007, Wang et 
al 2008). The catalytic domain of PDEs consists of 17 α-helices that arranged in 3 
subdomains that altogether form deep pocket in which the cNMP is bound and 
subsequently hydrolyzed (Ke 2004). Four areas are distinguished in the deep hydrophobic 
pocket: a metal-binding site (M site), core pocket (Q pocket), hydrophobic pocket (H 
pocket) and lid region (L region, Jeon et al 2005). The sequence alignment of PDEs 
revealed two conserved Hx3Hx24–26E sequences, corresponding with known zinc-binding 
motifs. Moreover, PDEs has been shown to require divalent cations for catalytic activity, 
especially presence of zinc at low concentrations is reported to be of high importance 
(Francis et al 1994).  Determination of crystal structure of PDEs revealed that the metal-
binding site forms the bottom of the pocket, and bind two metal ions, one of which has 
been determined to be Zn2+ and the other is thought to be Mg2+ or Mn2+ (Ke 2004, Jeon et 
al 2005).  
An important feature of PDEs is their substrate selectivity for cAMP or cGMP, which is 
determined by conformation of a glutamine residue within the core pocket area, thus 
called the glutamine switch (Zhang et al 2004). This particular glutamine can adopt 2 
different conformations depending on its surrounding protein structure. Each 
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conformation prefers either cAMP or cGMP. In nucleotide specific PDEs conformation is 
imposed to the concerned glutamine residue, thus allowing only binding of only one 
specific cNMP, while in non-specific PDEs this glutamine is allowed to rotate freely and 
possibly bind both of the possible cNMP almost without preference (Zhang et al 2004, Fi). 
Above mentioned variability of PDEs is also demonstrated by their different 
vulnerability to variety of small organic molecules, inhibitors of PDEs that are bound to 
the hydrophobic pocket. Although both PDEs and their inhibitors vary in structure, their 
interactions share common features (Joen et al 2005). The central ring of the 
ligand/inhibitor is held on the positions of purine ring of cNMP  by so called hydrophobic 
clamp and interacts with conserved glutamine of the glutamine switch, however inhibitor 
substances seem to avoid interaction with metal ions on the bottom of the hydrophobic 
pocket (Joen et al 2005). Inhibitor selectivity is determined by the shape of the 
hydrophobic pocket, yet whether it is the overall shape or rather specific residues, is a 
question not fully answered (Ke 2004). However most likely it will be the combination of 
both, while the contribution of both aspects might differ from case to case. In the case of 
PDE8a, single mutations of amino acids participating on forming the hydrophobic pocket 
have been reported to alter the inhibitor selectivity, since mutation of Tyr748 to Phe748 
cause otherwise IBMX insensitive PDE8A to be inhibited by it (Wang et al 2008).  
Although knowledge about structure of catalytic domain of PDEs still can be expanded, 
it is by now explored in good detail. In contrast, the structures of both N-terminal and C-
terminal regions remain elusive, mostly due to their complicated crystallization and 
variability (Conti and Beavo 2007).  
2.1.5 Evolution of PDEs 
Diversity and abundance of PDEs in vertebrates observed today has probably emerged 
by several rounds of gene, or eventually genome, duplication (Koyanagi et al 1998). Since 
all animal PDEs known so far contain phosphodiesterase class I catalytic domain shared 
with yeast PDE2, they are thought to diverge from one ancestral gene with a single 
domain (Conti and Beavo 2007, prosite). Considering the fact, that in yeasts there is only 
one PDE of class I and already in freshwater sponge Ephydatia fluvialis 4 PDE genes are 
detected, first duplication of PDE ancestral gene must have occurred early in the 
evolution between the animal-fungus split and the divergence of porifera and eumetazoa 
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(Koyanagi et al 1998). Expansion of PDE genes then continues, as is exemplified on the 
case of PDE4 which is duplicated again after divergence of Mixiniformes and before the 
divergence of teleosts, since further the evolutionary history of PDE genes in other 
vertebrates differ from that in teleosts (Johnson et al 2010). Early after the first 
duplications of PDE genes, rapid accumulation of amino acid substitutions was observed, 
however later when the duplicated genes become more established the mutation pace 
slowed down (Koyanagi et al 1998). Rapid accumulation of amino acid substitutions is not 
only sign of distant evolutionary history, since despite human PDE4A8 is highly similar to 
rat PDE4A8 in nucleotide sequence on protein level there are drastic changes in the 
length and composition of its N-terminal region, indicating that it must have happened 
recently after divergence of rodents and primates ( b 2005). Moreover this N-terminal 
region of human PDE4A8 is more similar in sequence to the PDE4B1 of Sus scrofa and 
Callithrix jacchus than to PDE4A8 in those species, suggesting recent evolutionary 
rearrangements (Johnson et al 2010).  
In mammals the required diversity of PDE proteome is achieved mostly via alternative 
splicing (Richter et al 2005), however this is not true in teleosts, where instead of 
alternative splicing additional duplication of PDE4 genes ensures the required diversity of 
PDE4 isoforms (Johnson et al 2010). The growing need for finely tuned and complex 
signaling during the course of animal evolution corresponds with increasing amount of 
different PDE proteins, achieved both by gene duplication and alternative splicing 
(Johnson et al 2010, Koyanagi et al 1998, Conti and Beavo 2007, MacKenzie  et al 2008). 
2.2 Signaling via cAMP 
In 1957 Rall, Sutherland and Berthet observed stimulation of liver phosphorylase by a 
heat stable factor that, as was shown later, contained adenosine, ribose and phosphate in 
1:1:1 molar ratio. Moreover this factor was present in fraction of cell lysates that 
contained membranes after response to addition of hormones. Then when purified factor 
was added to membrane free fractions of cell lysates it has activated phosphorylase, a 
physiological response that hormones alone could not elicit. It was the moment, when 
concept of second messengers was first formed (as reviewed in Beavo and Brunton 2002). 
Determination of the structure of this heat stable factor has revealed the original second 
messenger to be 3’,5’-cyclic adenosine monophosphate (cAMP; Beavo and Brunton 2002). 
18 
 
Sutherland was awarded a Nobel-prize for his discovery and research of cAMP dependent 
mechanisms. 
The first notion that cAMP signaling might be compartmentalized in the cell comes 
from studies of Brunton and coworkers (Edwards et al 2011). The cAMP concentration 
has risen to the same extent in cardiac muscle cell in response to stimulation of either 
isoprenaline or PGE1. However only stimulation by isoprenaline activated the glycogen 
phosphorylase and increased the ventricular pressure. Thus observed physiological 
response depended rather on the way the cAMP concentration rise was triggered (Hayes 
et al 1980) 
Nowadays the concept of compartmentalized cAMP signaling is an accepted part of a 
paradigm (Edwards et al 2011). In the following chapter it is reviewed how local gradients 
of cAMP can be achieved or how is it possible that the cell can accommodate multiple 
signaling circuits that use the same second messenger.  
 
2.2.1 Architecture of cAMP signaling pathway 
Cellular signaling events that implement cAMP can be divided into several steps. First, 
the signal is triggered and initiates the activation of adenylyl cyclase (AC). Second, 
generated cAMP transduces the signal to efector protein that results in physiological 
response. Finaly, the signal is terminated by hydrolyzing cAMP into AMP by PDEs 
(Serezani et al 2008; Kamenetsky et al 2006).  
Conventionally, the first trigger is the binding of extracellular (first) messenger to 
heptahelical G-protein coupled receptor (GPCR; Serezani et al 2008).  There are more 
than 800 genes coding for GPCRs in human genome that transmits their signal further 
through heterotrimeric guanine nucleotide binding proteins, also called simply G proteins. 
Binding of extracellular messenger to GPCRs results in conformational change, that 
triggers exchange of GDP for GTP in the G-protein thus initiating activation and 
dissociation of the Gα subunit from the complex (Cotton and Claing 2009).  The 
dissociated Gα subunit interacts with transmembrane adenylyl cyclase that converts ATP 
into cAMP. There are four major families of G proteins: Gs, Gi/o, Gq/11 and G12/13 (Cotton 
and Claing 2009), yet only Gs and Gi/o are known to interact with transmembrane adenylyl 
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cyclase and while Gs promotes generation of cAMP, Gi/o suppresses it (Kamenetsky et al 
2006).  
Adenylyl cyclase (AC) translates the information coming from the cell exterior through 
G-protein into cAMP signal (Kamanetsky et al 2006). The whole family of ACs consists of 
10 genes in the human genome. In addition, alternative splicing has been reported in at 
least some of their transcripts, thus increasing the diversity of AC proteome. Nine of ten 
AC genes code for proteins that include transmembrane domain and interact with GPCR. 
In contrast the last AC gene codes for soluble protein with AC activity that is thought to be 
regulated by calcium ions and bicarbonate (Kamanetsky et al 2006).  
After conversion from ATP by AC, cAMP reaches the effector protein and induces 
functional changes, resulting in altered activity and subsequently to the physiological 
response. Three species of proteins are considered to be the effector proteins of cAMP. 
Protein kinase A (PKA) binds cAMP molecule and then releases its catalytic unit that 
phosphorylates numerous protein substrates (Kamanetsky et al 2006). Exchange protein 
directly activated by cAMP (EPAC) promotes the release of GDP and binding to GTP, thus 
activating small GTPases (Rooij et al 1998) and cyclic nucleotide-gated ion channels 
translate the cAMP signal into voltage response (Cukkemane et al 2011). Downstream 
from the effector protein the signaling cascade is branched extensively and includes 
plenty of processes such as phagocytosis (Ballinger et al 2010), T-cell adhesion (Vang et al 
2010), regulation of contraction strength in hearth (Beca et al 2011) or glycogen 
metabolism (Hayes et al 1980). 
Duration of the signal is vital for the proper course of the response thus appropriate 
termination of the cAMP signal is achieved via hydrolysis of 3’-5’ phosphodiester bond by 
PDEs (Serazani et al 2008). Since, as stated above, variable processes are controlled by 
the cAMP signaling cascade. Considering their different nature, different duration and 
speed of the signal termination is required by each of them and such diversity of 
requirements is covered by the vast array of PDE isoforms (Conti and Beavo 2007). 
The general structure of cAMP signaling pathways is modular in nature, since for any 
position within the cAMP signaling pathway there is a pool of different proteins and 
isoforms that could possibly occupy it. Broad pool of available elements allows their 
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combination into finely tuned signaling circuits that are implemented in variable 
processes within the cell. 
 
2.2.2 Compartmentalized signaling 
The idea of compartmentalized signaling through cAMP after the notion that elevated 
concentration of cAMP might result in distinct physiological outcomes depending on the 
agents used to provoke it (Hayes et al 1980, Edwards et al 2011). Then years of research 
brought significant amounts of biochemical evidence that it is physiologically relevant 
(Houslay and Adams 2003) and more recently it has become possible to visualize cAMP 
gradients in living cells (Edwards et al 2011). Advances in fluorescent microscopy 
techniques and design of genetically encoded florescent probes, especially those 
implementing principles of Förster resonance energy transfer (FRET) rendered such a 
visualization possible and broadly available (Edwards et al 2011).  
 
2.2.2.1 Shaping the gradient 
Establishing concentration gradient of cAMP in the cell is a very complex and dynamic 
process. It involves generation of cAMP by ACs, its diffusion in cytosol and hydrolysis by 
PDEs (Serezani et al 2008). The kinetics of each mentioned process plays important role in 
the resulting distribution of cAMP across the cell. Localized mostly on cytoplasmic 
membrane, when stimulated, ACs are thought to release “clouds” of cAMP that if not 
sustained move rapidly into cytosol, since diffusion rate of cAMP is in a range between 
130 to 700 µm2 sec-1 (Houslay et al 2007). In contrast, regions within the cell with high 
abundance of PDEs are viewed as cAMP ‘sinks’ that locally drains cAMP (Edwards et al 
2011). Another important role of PDEs is hydrolysis of freely diffusing cAMP in the 
cytosol. Saturation of cytosol with cAMP prevents establishment of any cAMP gradient. 
Thus by keeping the concentration of cAMP in the cytosol low PDEs confine the formation 
of cAMP gradients around the source of its generation and channel the signaling around 
specific signaling modules (Houslay et al 2007). In other words PDEs maintain the 




2.2.2.2 Role of scaffold proteins 
To provide evidence on how the scaffold protein may influence or form signaling 
module, role of muscle specific A-kinase anchoring protein (mAKAP) is described here. 
Importance of proper positioning of PKA by AKAP was shown in skeletal muscle, where 
ablation of this interaction resulted in inability of PKA to phosphorylate its substrate, L-
type Ca2+ channels that would otherwise lead to potentiation of the muscle cell and 
subsequent increase of developed force after stimulus (Johnson et al 1994). Thus AKAPs 
are thought to direct protein phosphorylation by proper positioning of PKA nearby its 
corresponding substrate and by ensuring its exposition to the appropriate cAMP gradients 
or events (Pawson and Scott 1997). This view has been further supported by recently 
provided evidence that mAKAP ensures the appropriate position of PKA in relation to AC 
by binding both of them (Kapiloff et al 2009). As seen here on the example of mAKAP, 
where binding of PKA by mAKAP condition the phosphorylation of L-type Ca2+ channels, 
the topology of crucial enzymes of cAMP signaling pathway has dramatic influence on the 
speed of signal transduction and even determine the success of the transmission 
(Johnson et al 1994, Edwards et al 2011).  
Regulation of the duration of the signal and it´s termination is further secured by 
interaction of mAKAP with PDE4D3. As was already mentioned that this interaction is 
isoform specific thus providing fine tuning of the formed signaling module (Dodge et al 
2001). The complex formed by mAKAP, PKA and PDE4D3 is further extended by 
interaction of PDE4D3 with Epac-1 and subsequently with kinases MEKK, MEK5 and 
especially ERK5 that is capable of regulating PDE4D3 activity (Dodge-Kafka et al 2005). 
Dodge-Kafka and colleagues prepared FRET reporter construct simulating the structure of 
mAKAP-PKA complex. After initial stimulation the PKA kept reporter site phosphorylated 
thus allowing FRET to occur stably for time period exceeding 15 minutes. However, 
another construct prepared by the same group that included portion of mAKAP capable 
of binding PDE4D3 generated localized pulse of FRET signal. The conclusion of this 
experiment was that the presence of the proteins bound to the complex through PDE4D3, 
as well as the presence ofPDE4D3 itself, renders the signaling module capable of 
producing distinct pulses of cAMP or PKA activity (Dodge-Kafka et al 2005).  
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 Implementing organization of the oligomeric structure by AKAP and principle of 
negative feedback loop involved - a distinct signaling circuit is formed that exploits the 
spatio-temporal constrains of cAMP distribution in cell in genuine manner that prevents 
crosstalk among other signaling pathways. 
2.2.2.3 Lipids and membranes in cAMP signaling 
Organization of biological membranes and role of lipids and proteins in it remains still a 
controversial topic. The new concept of lipid rafts (membrane microdomains enriched 
with saturated long faty acid contain phospholipids, cholesterol and proteins with 
hydrophobic posttranslational modification – eg. Myristoylation, palmitoylation, 
prenylation, GPI) has evolved from the model of simple fluid mosaic where lipids have just 
passive structural role. Original mechanistic concept of lipid rafts evolved into a complex 
model that still uses the term lipid raft, yet the understanding is different (Owen et al 
2012). Proteins are according to it clustered on the cell membrane, and in this aspect the 
evidence is unequivocal (Douglas and Vale2005, Owen et al 2010). The lipid composition 
varies across the membrane and lipid environment is capable to mediate molecular 
interactions, however whether the emphasis should be put on the protein-protein or 
rather on the lipid-driven interactions remains a subject of controversy (Cebecauer et al 
2009). 
It has been proposed that organizing GPRCs with ACs in membrane microdomains 
might provide additional way how to compartmentalize cAMP signaling (Houslay et al 
2007). Some of the ACs are thought to localize into lipid rafts and caveolae as is the case 
of AC8 (Kamanetsky et al 2006, Cooper et al 2003). It has been shown recently that 
AKAP79 interacts with AC8 and regulates its activity (Willoughby et al 2010). Furthermore 
evidence suggests that this interaction is mediated by lipid environment of plasma 
membrane, especially because the functional association of AKAP79 with AC8 requires 
palmitoylation of membrane bound AKAP79 (Delint-Ramirez et al 2011).  
The possible role of lipids and plasma membrane in formation of local cAMP gradient 
points poits out the fact that some of PDEs contain lipid anchors or domains capable of 
inducible interaction with phospholipids as for example PDE4A1 that contains TAPAS-1 
domain (Baillie et al 2002), PDE3 which has been shown to contain transmembrane region 
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(Shakur et al 2000) or PDE10A2 which membrane localization depends on plamytoylation 
of its cysteine 11 (Charych et al 2010).  
Enzymes competent to form cAMP gradients are known to interact more or less 
directly with lipids on the plasma membrane and some of these lipids are associated with 
putative membrane microdomains. The organization of biological membranes is a 
complicated topic, that has not been solved yet (Owen et al 2012), therefore concepts of 
membrane spacial microdomain organization is not yet implemented into general 
paradigm of cAMP signaling. However, despite this, there is evidence, that interactions 
with lipids or mediated via lipids are important for assembly of cAMP signaling circuits 
(Delint-Ramirez et al 2001) 
2.2.3 Immune system and cAMP signaling 
Across the animal kingdom the usage of cAMP is widespread and the physiological 
responses in which it plays crucial roles are extremely variable. Just to name a few, cAMP 
plays important role in regulation of blood pressure, cognitive functions as well as in 
immune system (Beca et al 2011, Serezani et al 2008). It is the immune system that our 
laboratory is especially interested, thus reviewed here will be the function of cAMP in 
immune cells. 
Innate immune functions of monocytes, macrophages and neutrophils, together 
simply referred to as phagocytes, is suppressed by elevated levels of intracellular cAMP 
(Serezani et al 2008). Production of both pro- and anti-inflammatory is modulated by 
cAMP, however individual cytokines differ in details of the regulation. Both Epac-1 and 
PKA participate in control of cytokine production, however they might act individually, in 
concert or against each other (Aronoff et al 2006). For example alveolar and peritoneal 
macrophages produce tumor necrosis factor α (TNF-α) in response to bacterial 
lipopolysaccharide. This production is strengthened by addition of Epac-1 agonist, while 
abolished by PKA agonist, thus illustrating the different effect that stimulation of effector 
protein by cAMP might have (Aronof et al 2005, Aronoff et al 2006).  
Elevated levels of cAMP have been shown to inhibit phagocytosis. Detailed 
examination of this phenomenon revealed that phagocytosis requires undisturbed 
function of Epac-1 (Aronoff et al 2005). On the other hand, observation of Makranz and 
colleagues suggests that the resulting effect of PKA inhibition on phagocytosis depends 
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largely on the dose of inhibitor (Makranz et al 2006). In general the evidence shows that 
PKA plays a role in phagocytosis and might be differenty involved in particular cell types 
(Serezani et al 2008). 
Changes in local cAMP concentration during phagocytosis have been imaged recently 
by implementing FRET based Epac-1 biosensor (Ballinger et al 2010). Transient and 
localized bursts of cAMP have been observed in place of phagosome formation. This 
might seem surprising since elevated levels of cAMP have been rather linked to inhibition 
of phagocytosis (Aronoff et al 2005, Ballinger et al 2010). However, taking the local cAMP 
grandients into consideration, elevated levels of cAMP concentration may result into 
saturation of the cytosol by cAMP. High concentration of cAMP is thought to prevent 
establishment of local gradients and thus disrupt signaling (Houslay et al 2007). 
In addition to above mentioned processes, cAMP has been reported to mediate the 
elimination of phagocytosed microbes via inhibition of formation of the reactive oxygen 
intermediates (Aronoff et al 2005, Serezani et al 2007).  
Apart from its important role in innate immunity, cAMP regulates plethora of 
processes in cells of adaptive immune system. Chemotaxis of splenocytes has been 
reported to be abolished after treatment by AC activator forskolin or PDE inhibitor IMBX 
(Dong et al 2006). Adhesion of T-cell to endothelial cells, that precedes migration into the 
target tissue, has been shown to be disrupted after elevation of the intracellular cAMP 
levels (Vang et al 2010). On the other hand, excessive amounts of cAMP are required for 
the function of naturally occurring T regulatory cells (nTregs) that facilitates the 
suppression of other T-cells. The regulation of T-cells by nTregs is thought to involve 
transfer of large amounts of cAMP through gap-junction that the interacting cells form 
and subsequently by regulation of gene expression as a consequence of cAMP entry 
(Bodor et al 2012). 
Taken together, there are many signaling circuits leading to different cellular response, 
that implements cAMP as a second messenger (Serezani et al 2008, Bodor et al 2012, 
Houslay et al 2007). The precise details of their composition, formation and maintenance 
remain mostly unknown, although there are already some hints about how the specific 
function and interaction are ensured (Dodge-Kafka et al 2005, Johnson et al 1994). In the 
25 
 
mammalian tissues cAMP plays important role elsewhere, for example in crucial 
processes of immunity, circulation or cognition (Conti and Beavo 2007). 
2.2.4 Adenylate cyclase toxin-hemolysin produced by Bordetella pertussis 
Pathogens use various strategies to compete with the host defense mechanisms. 
Recent host-pathogen interactions are results of long term co-evolution and employ 
sophisticated molecular mechanisms.  One way how pathogens fight on longer distance is 
secretion of soluble toxins which can alter cellular physiology in many ways, for example 
interfering with intracellular signalization (Fiser et al 2012). As was mentioned in previous 
chapters, cAMP is important second messenger and altering its concentration is possible 
alter the cellular responses or even kill the cell of interest. 
Bordetella pertussis, the bacteria responsible for the whooping cough, secretes an 
adenylate cyclase toxin-hemolysin (CyaA) - a key virulence factor. CyaA is an unusually 
large, 1706-residue-long, multifunctional secreted protein. It consists of an amino-
terminal adenylate cyclase (AC) domain, (400 N-terminal residues) and of an RTX (Repeat 
in ToXin) cytolysin moiety (about 1306 residues, Vojtova et al 2006). The unique feature 
of the RTX moiety is ability to insert into membranes and subsequent translocation of the 
AC domain into cell cytosol (Bumba et al 2010). In the cytosol AC domain binds 
calmodulin and catalyzes transformation of ATP to cAMP. High enzymatic rate of this 
reaction dramatically increase intracellular concentration of cAMP, thereby cellular 
signaling is disrupted subsequently CyaA-catalyzed production of cAMP can promote 
necrotic cell death or apoptosis Above mentioned function depend on covalent post-
translational fatty-acylation of CyaA at internal lysine residues (Vojtova et al 2006).  
The capacity of recombinant purified Cya A to bind to the cells, translocate the AC 
domain into the cell interior and intoxicate the cell via elevated cATP concentration 
makes for us CyaA as a tempting tool for studying activity of PDE, namely in the context of 
membrane microdomains, compartmentation of the intracellular signaling and possible 




2.3.1 Gene organization and tissue distribution 
In the light of what was said by now many properties of PDE8A will not be surprising 
and correspond well with the attributes of other PDEs.  
Gene coding for PDE8A spans at least 80kbp and consists of 23 exons and 22 introns 
which are spliced into five variants, labeled as PDE8A 1-5. Of the transcript variants 
PDE8A1 contains the longest ORF (2490bp) that consists of 22 exons excluding only exon 
8, which would eventually disturb PAS domain coded partly by neighboring exons 7 and 9. 
In addition to exon 8 PDE8A2 excludes also exon 9 and PDE8A3 also exon 7. So far 
mentioned transcript variants share common start codon, in contrast to PDE8A4, which 
lacks exon 7 and 8, and PDE8A5 that despite consisting of all 23 exons are translated from 
alternative start codon located on 9th exon. Thus intriguingly only 4 different proteins are 
produced. (Wang et al 2001).  
Just 11 bp upstream from the transcription site lies a TATA box and further upstream, 
another 820 bp stretches the CG-rich (70% CG content) promoter of PDE8A capable of 
harboring transcription factors such as as Oct-R, myogenin and Arnt (Wang et al 2001). 
The promoter ensures presence of PDE8A1 transcripts in testis, spleen, lymph nodes and 
various cells of immune systems like Th1, Th2 or activated T-cells where amount of 
transcripts is reported to rise upon lymphocyte activation (Wang et al 2001, Glavas et al 
2001). Transcript of PDE8A2 is found in the same tissues as that of PDE8A1, however the 
amounts differ. Levels of PDE8A1 are highest in testis, while PDE8A2 is found mostly in 
spleen, and similarly such differences are found across the tissues where both transcripts 
were detected (Wang et al 2001) 
2.3.2 Features and structure of PDE8A proteins 
The PDE8A was recognized simultaneously by two research groups, one identified the 
human PDE8A (Fisher et al 1998) and the other focused on protein from mouse (Soderling 
et al 1998). Both isolated proteins were highly cAMP specific with only background cGMP 
hydrolyzing activity (Fisher et al 1998, Soderling et al 1998). The catalytic domain of 
isolated PDE8A protein showed only limited degree of sequence identity to the catalytic 
domains of already known cAMP specific PDEs. While sequence identity between catalytic 
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domains within the members of PDE gene family is usually more than 85%, the catalytic 
domain of PDE8A had no more that 40% of sequence identical to any known PDE family at 
that time. Catalytic domain of PDE8A was found to be most similar to the PDE4 with 
38.5% of amino acid sequence identity and least similar to the catalytic domain of PDE6 
with sequence identity only 20.2% (Fisher et al 1998). Moreover, PDE8A was not inhibited 
by most of the inhibitors tested, with dipyramidol as the only exception (Fisher et al 1998, 
Soderling et al 1998). Based on these data, PDE8A was descriptively named as high 
affinity cAMP specific and IBMX-insensitive PDE. 
Kinetic properties of PDE8A have been determined several times using different PDE8A 
variants. For full-length mouse PDE8A, KM of 0.15µM was reported (Soderling et al 1998) 
and N-terminally truncated human PDE8A displayed value 0.055µM (Fisher et al 1998). In 
contrast KM=1.8µM was reported for isolated and refolded PDE8A catalytic domain 
fragment (Wang et al 2008, Yan et al 2009). This disproportion is probably due to N-
terminal negative regulatory effect on enzymatic activity (Wang et al 2008). Catalytic 
activity of PDE8A1 is dependent on presence of Mg2+ or Mn2+ (Fisher et al 1998, Yan et al 
2009). 
The structure of PDE8A catalytic domain has been determined and revealed what 
already specific pharmacological profile together with the low degree of sequence 
identity towards other PDEs indicated. -  unique conformation of catalytic pocket 
(Soderling et al 1998, Wang et al 2008). While in the catalytic pocket of PDE8A1 is a 
tyrosine residue in position 748, in most other PDEs homologous position is occupied by 
phenylalanine. Mutation of Tyr748 into phenylalanine renders PDE8A1 susceptibility to 
various inhibitors, thus implying the crucial role of Tyr748 in PDE8A1 inhibitor selectivity 
(Wang et al 2008).  
Based on the sequence analysis, PDE8A was predicted to contain PAS domain 
(Soderling et al 1998). Present in many proteins of all kingdoms of life, PAS domains are 
thought to serve as universal signal sensors and interaction platforms, mediating 
processes such as diverse ligand binding or protein-protein interaction (Möglich et al 
2009). Presence of PAS domain was confirmed in PDE8A1 however splice variant PDE8A2 
omits exon 9, that codes for its C-terminal part, resulting into protein with incomplete 
PAS domain (Wang et al 2001).  In PDE8A1 PAS domain mediates binding to IκB that 
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subsequently results in increased enzymatic activity (Wu et al 2004). Moreover, KM of 
cAMP hydrolysis of the PDE8A1 catalytic domain produced separately is 1.8µM compared 
to KM of PDE8A1 fragment, that in addition to catalytic domain contains also PAS domain, 
is 0.28 µM which is approximately 6-fold difference (Wang et al 2008, Yan et al 2009). 
Such differences indicates important role of PAS domain in regulation of PDE8A1 function 
(Yan et al 2009) 
Apart from PAS domain activity of PDE8A1 is further regulated by PKA phosphorylation 
at serine 359 (Brown et al 2012). Similarly to PDE4D3, also PDE8A1 is thought to be a part 
of a feedback loop, where higher cAMP level triggers PKA activation that subsequently 
phosphorylate PDE8A1 at serine 359 (Brown et al 2012).  
Although more potential regulatory regions were proposed for PDE8A, such as REC 
domain, phosphorylation sites for various protein kinases and putative acylation sites, 
their functional role has not been assessed yet (Wang et al 2001, Brown et al 2012). Out 
from these, phosphorylation of PDE8A1 at serine 359 is the only post-translational 
modification proven and published so far (Brown et al 2012). 
2.3.3 Role of PDE8A in physiological processes 
Physiological role of PDE8A has not been studied extensively so far, mostly due to 
absence of specific inhibitor (Vang et al 2010, Brown et al 2012). Although without further 
details about mechanisms PDE8A was already recognized in diverse physiological 
processes (Dong et al 2006, Vang et al 2010, Shimizu-Albergine et al 2012, Patrucco et al 
2010). 
At both transcription and protein level PDE8A is up-regulated in CD4+ T-cells upon 
their activation by CD3 and CD28 thus suggesting its role in this cell type (Glavas et al 
2001). Examination of lymphocytes chemotactic migration toward CXCL12 (stromal cell-
derived factor 1) revealed that after activation migration of lymphocytes is degree of 
inhibition by FSK and IMBX decreases (Dong et al 2006). Moreover migration of 
lymphocytes is not affected by PDE4-selective inhibitor piclamilast neither by PDE7-
selective inhibitor, however is greatly inhibited by dipyramidol (Dong et al 2006). Such 
pharmacological profile corresponds well with that of PDE8A, which expression levels are 
increased upon lymphocyte stimulation, thus it was deduced that PDE8A is crucial for 
chemotactic behavior of lymphocytes (Dong et al 2006, Glavas et al 2001). In addition to 
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lymphocyte migration PDE8A has been shown to regulate the adhesion of T-cells to 
endothel via regulation of integrin expression (Vang et al 2010).  
High levels of PDE8A transcript were reported from testis (Wang et al 2001) and 
subsequently PDE8A protein has been found in leydig cells (Vasta et al 2006). In concert 
with PDE8B and PDE4, PDE8A was found to control steroidogenesis in leydig cells (Vasta 
et al 2006) as well as in the cells of adrenal gland (Tsai et al 2011). In addition PDE8A has 
been reported to regulate potentiation of contraction of ventricular myocytes (Patrucco 
et al 2010), however no systematic long term research on the physiological roles of 
PDE8A is conducted, most probably due to the lack of selective inhibitor (Brown et al 
2012, Vang et al 2010). Recently a PDE8 specific inhibitor has been reported (Vang et al 




3 Materials and methods 
3.1 Material 
3.1.1 Laboratory machines 
autoclave PS20A (Chirana), CCD camera Exwave HAD (Sony), centrifuge Universal 16R 
(Hettich Zentrifugen), centrifuge Universal 32R (Hettich Zentrifugen), centrifuge K26D, 
benchtop centrifuge Minispin Plus (Eppendorf), thermal cycler PTC100 (MJ Research), 
thermal cycler XP (Bioer), glass electrode pH meter AD1030 (Adwa), thermoblock 
Thermomixer comfort (Eppendorf), custom made electrophoretic set (J. Macha), inverted 
microscope IX-71 (Olympus), inverted mikroscope IX-81 Cell’R’ s equipped with 
fluorescent filters U-M3DAFITR (Olympus), spectrophotometer UV-1601 (Shimadzu), 
trans-illuminator TCP-20MC (Vilber Lourmat), set of mechanic pipettes EpResearch pipet 
(Eppendorf), Nanodrop ND-1000 (Thermo scientific), cytometer LSRII (BD), Laminar flow 
biosafety cabinet EF/B (Clean Air) confocal microscope Leica TCS SP2 (Leica) equipped for 
live cell imaging, shaking incubator NB-205 (N-Biotek), orbital shaker incubator (Neq), DC 
power source Power Station 300 (Labnet), spectrophotometer UV-1601 (Shimadzu), 
weighting scale ABC plus 600H (ADAM Equipment), vortex MS1 minishaker (IKA), 
 
3.1.2 Chemicals and reagents 
10x Long PCR Buffer with MgCl2 (MBI Fermentas), 10x High fidelity PCR Buffer with MgCl2 
(MBI Fermentas), 10x PfuUltra II reaction Buffer (Stratagene), 10mM MgCl2 (MBI 
Fermentas), β2-merkaptoethanol (Sigma), Annexin V-DY-647 (Exbio) agarose for 
electrophoresis (Invitrogen), ampicilin (Sigma), bromphenol blue (Sigma), CaCl2 (Sigma), 
4',6-diamidino-2-phenylindole (DAPI; Sigma), agarosa pro elektroforesu (Invitrogen),  
ampicilin (Sigma), D-MEM (Gibco), RPMI 1640 (Gibco) deoxyribonucleotides (dNTP, MBI 
Fermentas), ethylenediaminetetraacetic acid (EDTA, Sigma), calf intestine alkaline 
phosphatase (CIAP, MBI Fermentas), T4 DNA ligase (MBI Fermentas), phalloidin-
AlexaFluor 568 conjugate (Molecular probes), phenol (Lachema), fetal bovine serum (FBS, 
Gibco), formaldehyde (Sigma), geneticin (Gibco), glukose (Lachema), glutamine 
(SEVAPHARMA), chloroform (Lachema), kanamycin (Sigma), KH2PO4 (Lachema), Zyppy 
plasmid miniprep II kit Zymmo research), Zymoclean gel DNA recovery kit (Zymmo 
research), cover glass slides round 8mm (Hirschmann), Lipofectamine 2000 (Invitrogen), 
SOC medium (Invitrogen), methanol (Lachema), MgCl2 (Sigma), Urea (Lachema), Mowiol 
4-88(Calbiochem), Na2HPO4.12H2O (Lachema), NaCl (Lachema), NaN3 (Sigma), NH4Cl 
(Lachema), Nuclease free H2O (MBI Fermentas), Nutrient agar (OXOID), Glass bottom 
petri dishes for live cell imaging (Mat Tech), Disposable plastic Pasteur pipettes and 
pipette tips (Nunc, Eppendorf), Disposable plastic plates and flasks for cell culture (Nunc), 
glass slides for microscopy 76x26 mm (Hirschmann), primers and olignucleotides (Sigma), 
DMSO solution (Sigma), buffers for restriction endonucleases (MBI Fermentas), restriction 
endonucleases (MBI Fermentas), sterile Trypsin-EDTA, 10x (Sigma), LA DNA polymerase 
(Top-Bio), PfuUltra II Fusion HS DNA polymeraqse (Stratagene), 
tris(hydroxymethyl)aminomethan (Tris, Sigma), Tryptose Phosphate Broth (OXOID), Triton 
X-100 (Sigma), GeneRuler™ DNA Ladder Mix, 100-10,000 bp (MBI Fermentas), Ethidium 
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bromide homodimer (Molecular probes), Ethidium bromide (Sigma), H3BO3 (Lachema), 
cyclase toxin from Bordetella pertussis (cya A, kindly provided by Peter Šebo), Isopropyl β-
D-1-thiogalactopyranoside IPTG (Sigma), 
5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal, Sigma) 
3.1.3 Vectors 
pmCit-N3 was provided by Lukáš Falteisek as vector carrying PDE8A1(N) constructs. 
Vector is designed for expression of proteins with citrine fluorescent tag fused to their C-
terminus in mammalian cells. It was derived from pEGFP N3 (Clontech) by exchange of 
region coding for fluorescent tag so that citrine replaced GFP in the original vector.  
Restriction sites BamHI and BsrGI were used for this exchange. Other features of the 
original vector were retained. 
 
pGem-T easy was obtained from Promega (Promega Corporation) as a part of pGem-T 
Easy Vector System for cloning of PCR products. It is supplied linearized by EcoRV with 
added T overhangs and allows blue/white screening of recombinants. 
 
3.1.3.1 Plasmids for analysis of alternative splicing 
PDE8A_c1_2010, PDE8A_c8_2010 and PDE8A_D_tupo used for analysis of alternative 
splicing of PDE8A were left overs form unsuccessful attempts to clone PDE8A1.  
3.1.4 Solutions 
If not stated otherwise, solutions were kept in refrigerator at room temperature on light. 
 
EDTA 2% 
4g EDTA dissolved in 100 distilled H2O; alkaline pH adjusted by 6 ml of 10M NaOH to 
facilitate dissolving of EDTA; pH adjusted back to 7.2 by 4 ml of 6M HCL; water added to 
final volume 200 ml 
 
Mowiol with DAPI 
20% (w/v) glycerol; 10% (w/v) Mowiol 4-88; 0.1 M Tris.HCl; pH 8.5; DAPI 1µg/50ml, stored 
in dark at 4°C. 
 
Buffer TUC 
50mM tris; 8M urea; 0.2 mM CaCl2; stored at -20°C 
 
10x PBS 
79 g NaCl; 1,1 g KCl; 29 g Na2HPO4.12H2O; 3,1 g KH2PO4; distilled water added till final 
volume 1 l 
 
Agarose gel electrophoresis 
 
TBE buffer 





50% glycerol; 0.13 M EDTA; 0.12% bromphenol blue; pH 8.0 
 
Cultivation of E. coli  
 
TPB 
29.5 g/l Tryptose Phosphate Broth; sterilized at 121°C for 15 min in autoclave; 
skladováno při 4°C 
 
Nutrient agar  
28 g/l Nutrient Agar; sterilized at 121°C for 15 min in autoclave; antibiotics added after 
medium have cooled to 40°C 
 
1M MgCl2 
20.3 g MgCl2 . 6H2O/100 ml 
 
1M CaCl2 
11.1 g CaCl2/10 or 14.7 g CaCl2 . 2 H2O/100 ml 
 
Buffer 0.1M CaCl2 + 14%glycerol 50 ml 
80% glycerol 8.25 ml; 1M CaCl2 5 ml; H2O added till total volume 50 ml 
 
10x PBS 
79 g NaCl; 1,1 g KCl; 29 g Na2HPO4.12H2O; 3,1 g KH2PO4; distilled water added till final 




Water for cell cultures (“TK H2O”) 
Deionized water was sterilized at 121°C for 20 minutes in autoclaving machine 
 
D-MEM 
90% (v/v) D-MEM; 10% (v/v) FBS; 40 µg/ml gentamycin; 0,25 mg/ml glutamine; prepared 
sterile; storage at 4°C 
 
RPMI 1640 
90% (v/v) RPMI 1640; 10% (v/v) FBS; 40 µg/ml gentamycin; 0,25 mg/ml glutamine, β-
merkaptoethanol 0,05 mM; prepared sterile; storage at 4°C 
 
PBS TK 
10x PBS (79 g NaCl; 1.1 g KCl; 29 g Na2HPO4.12H2O; 3.1 g KH2PO4) TK H2O added till final 
volume 1l; filtered and sterilized at 121°C for 20 minutes in autoclaving machine; diluted 
10x befor use by TK H2O  
 
EDTA 0.02% for cell culture application 




10x Trypsin EDTA for cell culture application (Sigma) 
5g porcine trypsin, 2g EDTA, 0,9% NaCl do 100 ml 
3.1.5 Laboratory organisms used 
3.1.5.1 E. coli strain TOP10 (Invitrogen) 
F- mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 deoR nupG recA1 araD139 
Δ(ara-leu)7697 galU galK rpsL(StrR) endA1 λ- 
(designed for cloning, slelcted endonucleases eliminated, suitable for amplification of 
large plasmids, blue/white screening – lac operon deleted and for α- complementation 
partly deleted lacZ introduced on ϕ80 
 
3.1.5.2 Raw 264.7 cell line 
Mouse leukaemic macrophage cell line established from tumor induced by Abelson 
murine leukemia virus. Morphology of the cells is similar to monocytes and macrophages. 
Cells are capable of pinocytosis as well as of phagocytosis (ATCC website). Cell line was 
kindly provided by P. Šebo. 
 
3.1.5.3 CHO cd11 cell line 
Adherent cell line with epithelial morphology established from Chinese hamster ovary 
cells. CHO cd11 was derived from the original line by establishing stable expression cd11, 
an α component of various integrins that is present on macrophages and utilized by cya A 







3.2.1 Site directed mutagenesis 
3.2.1.1 Eliminating mutations in PDE8A1 constructs 
Primers covering the single point mutations (Tab.  were designed so that the resulting 
sequence after amplification would match PDE8A1 (GI:47132535).  
primer 
designation 
primer sequence Tm 
8a_opr_I GTTTAAGTGTACAGTTACCAAGGAGGCTCAGGCTGTCCTTGCCTGTTTCCTGGACAAA 80°C* 
8a_opr_II ATGCATGAATTTATAGTATCGAGCAAGTCAGCCTTTTTTTCATTTATAGG 75°C* 






Reaction mixture consisted of: 
 
10x LA polymerase buffer 5µl 
primer F (25 µM) 2µl 
primer R (25 µM)  2 µl 
dNTP (10 mM)  1 µl 
template DNA 60 ng 
LA DNA polymerase (5U/µl) 0.5µl 
H2O 38,5 µl 
 
 
PCR was performed in 32 cycles with initial denaturation at 94°C for five minutes. Cycle 
parameters were: denaturation 94°C 20s; annealing 65°C 20s; elongation 68°C 1:20 (m:s). 
Products subsequently underwent agarose gel electrophoresis. Bend of corresponding 
length was extracted and cloned into pGem-T easy. 
 
 
3.2.1.2 Preparation of catalytically inactive PDE8A1 
Perry and coworkers (Perry et al 2002) successfully generated inactivated PDE4D5 protein 
by making single mutation Asp556 to Ala (D556A) in the catalytic site. Catalytic site is 
Tab 3.1 List of primers used for site directed mutagenesis in order to eliminate sequence conflicts between 
available PDE8A1 and PDE8A1 reference sequence (GI:47132535); Highlighted in yellow are sites of 
mutagenesis that reference sequence; Underlined are restriction sites BsrGI; NsiI and BamHI in primers 
8a_opr_I; 8a_oprII and 8a mAFP N3 R respectively; * indicated are melting temperatures for perfectly 




conserved among PDEs so that corresponding residue was identified in PDE8A1 protein 







The position of identified residue verified by examination of protein 3D structures 
available for catalytic domains PDE4D5 and PDE8A.  
Both strands of PDE8a_H2RB plasmid were amplified from primers 8aINA F and 8aINA R 
(Tab. 3.2) designed to introduce mutation of adenine at 2177 to cytosine (2177A->C; Fig. 
3.2) in 12 cycle PCR by PfuUltra II Fusion HS DNA polymerase. Reaction mixture and 












primer sequence Tm 
8aINA F  GCTGATTAAATGTGCTGCTGTGTCCAATCCCTGCC 75°C 
8aINA R  GGCAGGGATTGGACACAGCAGCACATTTAATCAGC 75°C 
Tab. 3.2 Primers for A2177C site directed mutagenesis 
 
10x PfuUltra II reaction buffer 5µl 
dNTP (10mM) 1µl 
DNA template 30-40ng 
Primer 8aINA F 125ng 
Primer 8aINA R 125ng 
PfuUltra II Fusion HS DNA polymerase 1µl 
H2O up to 50µl final volume 
Tab. 3.3 Content of PCR mixture for A2177C site directed mutagenesis 
  
            720       730       740       750       
             |....|....|....|....|....|....| 
PDE8A1   720 MLIKCADVSNPCRPLQYCIEWAARISEEYFS 750 
                 ||| |||  |||    |  |  || |  
PDE4D5   550 NMVHCADLSNPTKPLQLYRQWTDRIMEEFFR 580 
                  
Fig 3.1 Sequence alignment of catalytic domains of PDE8A1 and PDE4D5; 
Note the aspartate residue (at 726 in PDE8A and 556 in PDE4D that is 
important in ensuring binding of divalent cation and thus preserve 




2161  CTG ATT AAA TGT GCT GAT GTG TCC AAT CCC TGC CGA CCC CTG CAG   2205 
721   Leu Ile Lys Cys Ala Asp Val Ser Asn Pro Cys Arg Pro Leu Gln   735 
 
PDE8A1_inactivated 
2161  CTG ATT AAA TGT GCT GCT GTG TCC AAT CCC TGC CGA CCC CTG CAG   2205 
721   Leu Ile Lys Cys Ala Ala Val Ser Asn Pro Cys Arg Pro Leu Gln   735 
 
Fig. 3.2 Nucleotide sequence and its translation of PDE8A1 catalytic domain, before (up) and after 
site directed mutagenesis; Frame marks the target codon 
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  Initial denaturation 94°C 5:00 
12 
cycles 
Denaturation 94°C 0:20 
Annealing 55°C 1:00 
Elongation 72°C 2:10 
  Final elongation 72°C 3:00 
Tab. 3.4 Parameters of PCR run for A2177C site directed mutagenesis. 
 
After PCR run mixture was incubated for four hours with methylation sensitive restriction 
endonuclease DpnI that digest the parental DNA template, but preserve the newly 
synthetized DNA. Distinction is based on the methylated state of the DNA isolated from E. 
coli, while strands synthetized by PfuUltra II Fusion HS DNA polymerase in the PCR run are 
not. Chemocompetent bacteria were transformed by the resulting mixture.  
Since full-length PDE8A1 constructs contained CG rich segment, that would disturbed PCR 
amplification of the whole plasmid, PDE8a_H2RB that lacked this segment was used as a 
template. The whole sequence coding catalytically inactivated PDE8A was assembled 
afterwards by means of cloning and restriction enzymes.  
3.2.2 Transformation of chemocompetent bacteria 
Chemocompetent cells of E. coli strain were stored at -80°C. Before use the cell 
suspension was briefly thawed on ice. Either 0.3µl of plasmid DNA or 3µl of ligation 
mixture were added to 40µl of cell suspension and incubated on ice for 20 minutes. Cells 
were heat-shocked by incubation for 40s at 42°C and then cooled on ice for 2 minutes. 
Afterwards 200µl of SOC medium  were added and bacteria were incubated in 
thermoblock at 37°C and constant shaking (1200 rpm) for one hour. The suspension was 
plated on nutrient agar in petri dishes with appropriate antibiotics and incubated over 
night at 37°C. 
3.2.3 Plasmid isolation 
For routine needs Zippy Plasmid miniprep kit was used according to protocol provided by 
manufacturer. For this purpose bacterial cultures were grown in 3 ml of liquid medium on 
nutrient agar plate covering quarter or whole surface, depending on the amount of DNA 
needed. Bacterial cultures were grown in the presence of appropriate antibiotic. 
In case of full-length PDE8A1 constructs large amounts of DNA were need. For this 
purpose, Qiagen Maxi prep kit was used to isolate plasmid DNA from 0.5l of the culture. 
Procedure was performed according to protocol provided by manufacturer.  
3.2.4 Restriction digests 
3.2.4.1 Single digestion 
For single digestion buffer where desired restriction endonuclease is fully active was 
chosen. Reaction mixture composed of: 
Plasmid DNA 0.5-2µg 
10x concentrated buffer 1µl 
restriction endonuclease (10U/µl) 0.5µl 
H2O up to total volume 10µl 
 
Mixture was incubated at 37°C for an hour. 
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3.2.4.2 Double digestion 
Buffer where both desired restriction endonucleases were sufficiently active was 
chosen. Reaction mixture composed of: 
Plasmid DNA 0.5-2µg 
10x concentrated buffer 1µl* 
restriction endonuclease (10U/µl) 0.5µl 
restriction endonuclease (10U/µl) 0.5µl 
H2O up to total volume 10µl 
*In some cases use of 2x tango buffer was preferred thus 2µl were used instead 
Mixture was incubated 37°C for an hour. 
3.2.4.3 Scaling and analysis of DNA digestions 
In case of preparative digestion higher concentrations of DNA fragment were desired, 
thus higher amount of plasmid DNA was required in the reaction, what was especially 
important when the fragment of interest represented only a small portion of the plasmid. 
While performing digestion in >30µl ratios of DNA and buffer were conserved, while only 
half of the enzyme was used. As compensation mixture was incubated for two hours 
instead of one.  
To fragments, intended to serve as a vector in subsequent ligation, calf intestine alkaline 
phosphatase (CIAP) was added. 
Samples were subsequently run on agarose gel to separate individual fragments. 
3.2.5 Agarose gel electrophoresis  
Electrophoresis was performed at standard condition in 1% (w/v) agarose gel with 1 
μg/ml 
ethidium bromide in TBE under stable voltage 17 V per cm of gel length. Before loading 
bromphenol blue was added to the sample in 1:5 (Bromphenol blue:Sample) ratio. For 
short DNA fragments (<300pb) thicker 2% agarose (w/v) gel was used. Gene Ruler DNA 
ladder mix was loaded beside samples. After the run gels where examined on UV-
transluminator and pictures were taken by CCD camera Exwave HAD with “quick photo 
micro” software. 
3.2.6 Extraction of DNA fragments from agarose gel 
DNA fragments were separated on agarose gel electrophoresis. Upon examination on UV 
transluminator, fragments of desired length were excised by scalpel at maximum possible 
speed to minimize DNA damage by UV light and transferred to test tube. DNA was 
extracted by ZymocleanTM gel DNA recovery kit (Zymmo research) according to protocol 




3.2.7 Ligation of DNA 
Vectors and fragments obtained from the follow-up steps of restriction, electrophoresis 
and DNA extraction were ligated together. Ligation mixture composed of 
 
10x T4 DNA ligase buffer 1µl 
Linearized vector 100-500ng 
insert  in 1:1 ratio to vector 
T4 DNA ligase (5 Weiss U/µl)  0,5 µl 
 
and was incubated at room temperature for an hour. The ligation mixture was then used 
to transform TOP10 chemocompetent bacteria, a strain of E. coli. The vector insert molar 
ratio was approximately kept by putting approximately same amount of plasmid DNA 
already into the DNA digestion. If ligation failed procedure was repeated with several 





3.2.8 Sequence determination of PDE8A1  
Primers used for sequencing are listed in the table and their distribution on PDE8A1 
coding sequence is shown in figure. Sequence was determined in Laboratory of DNA 
sequencing at Faculty of Science (Charles University in Prague). After every step during 





primer sequence Tm 
8aN_F AATCTCGAGATGGGCTGTGCCCCGA 72°C *  
8aN_R AATGGATCCTTCTTGCCGCTGCCG 64°C 
8aIM_1_R CTCGAGTTATGGGACATCATCAAGGGAG 60 °C 
8aIM_2_F GGATCCACTGAGTTATATTCACCACAGTT 59 °C 
8aIM_3_F GGATCCATCAACAAACCCTTGGCAAC 59 °C 
Tab.X List of primers used for sequencing of PDE8A1 constructs. Primers were 
originally used for cloning of segments of PDE8A1 thus they contain restriction 
sites that do not hybridize with PDE8A1 coding sequence. Melting temperatures 
provided include this into consideration. Exception to this 8aN_F (T m denoted by 
star) where underlined restriction site has been incorporated into PDE8A1 






Fig. 3.3 Distribution of sequencing primers 
across the PDE8A1 gene. Positions are 
proportional. Downwards arrows indicate 
primer orientation toward 5’-end of CDS. 
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3.2.9 Cell cultures 
3.2.9.1 Cultivation conditions 
All cell lines used were kept in stable 5% CO2 atmosphere at 37°C. CHO cd11 cells were 
grown in D-MEM medium, while RAW264.7 cells were kept in RPMI 1640, both media 
contained 10% fetal bovine serum.  
 
3.2.9.2 Passages of cell lines 
From adherent cell line CHO cd11 cultivation medium was removed, afterwards were 
cells rinsed by PBS and subsequently covered by minimal volume of PBS containing 0.5% 
trypsin and 2.0% EDTA. After brief, approximately 5 minute long, incubation they were 
flushed from the cultivation surface by the stream of the passaging solution and 
resuspended.  Medium was added to 10% of the cell suspension for further cultivation. 
Similarly cultivation medium was removed from RAW264.7 cells, then 3 gentle rinses by 
PBS followed and afterwards, since adhesion of RAW264.7 to cultivation substrate is very 
weak, cells were resuspended by vigorous streaming of minimal volume of PBS over 
them. In cultivation flask 10% of cell suspension was kept and medium was added. 
RAW264.7 required fresh medium twice a week.  
3.2.9.3 Transformation of cell lines by lipofectamine transfection reagent 
Freshly passaged cell suspension was distributed evenly into wells of experimental plate. 
Amounts were approximately adjusted so that the next day would cells reach 90% 
confluency. 
Transformation of the cells was done by Lipofectamine 2000 according to protocol 
provided by the manufacturer. Amounts of reagents and DNA used for transfection were 
adjusted to volumes of cultivation media and size of the well according to scale provided 
in the protocol. For one well of 24-well plate transfecting particles were prepared as 
follows, first 2µl of lipofectamine reagent were diluted in 50 µl of medium without serum 
and antibiotics, then in the same volume of medium 0.8 µg of DNA used for transfection 
was diluted. After brief incubation diluted transfection reagent and DNA were mixed 
together and incubated for 25 minutes, then added to cultivation well.   
To prevent toxic effect of the reagent on cell viability, medium was exchanged 8 hours 
after transfection. Cell culture was screened for transfected cells 8-24 hours afterwards. 
3.2.9.4 Preparing cell lines expressing variants of PDE8a for microscopy 
Cells were plated into cultivation wells containing microscopic glass slides one day before 
transfection and left to grow up to 90% of confluency. Transfection procedure was 
performed as described in previous clause. Mostly 24-well plates were used. If used, 
transferrin-alexa594 of final concentration 50µg/ml or mitotracker-alexa594 was added 
to cultivated cells 2 hours before fixation.  
3.2.9.5 Fixation and preparation of specimen for microscopy 
For fixation medium was removed and 4% formaldehyde was added to cells for 20 
minutes without prior rinse. After fixation cells were rendered permeable by incubation in 
0.5% triton X-100 in PBS for 1 minute and rinsed with PBS for 3 times. If phalloidin-
allexa594 was used to stain actin cytoskeleton, it was added after this step (0.2U per 1.9 
cm2 of cultivation surface). 
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Glass slides were then removed from cultivation plate and fixed on microscopic slide with 
drop of mowiol-dapi. Specimens were examined by Cell’R’ microscopic system.  
 
3.2.9.6 Preparation of samples for flow cytometry 
Supernatants were collected from cultivation wells that were subsequently gently rinsed 
by PBS for 3 times. Cells were incubated in minimal volume of 0.02% sterile EDTA for 15 
minutes to weaken their adherence to cultivation surface. Cells were resuspended and 
kept on ice before further processing. 
If larger samples were used, the collected cell suspensions were centrifuged for 4 minutes 
at 250g at in pre cooled centrifuge. Supernatant was discarded and cells were 
resuspended in approximately 200µl of 0.02% EDTA and analyzed subsequently. 
For staining by annexin V collected samples were centrifuged for 4 minutes at 250g in 
cooled centrifuge. Supernatant was discarded and cells were resuspended in annexin V-
binding buffer and centrifuged again, this step was added in order to ensure sufficient 
Ca2+ for annexin binding, that that was depleted by EDTA. Pellet was resuspended in 
annexin binding buffer with added annexin V and incubated for 20 minutes at room 
temperature.   
Cells were kept on ice and directly before analysis on LSR II (BD) either 5µl of 
DAPI(100µg/ml) or 3µl of EtBr (2mM) were added to cell suspension.  
3.2.9.7 Treatment of cell cultures by cya A 
Concentrated Cya A was kept frozen at -20°C in TUC buffer. Before addition to cells it was 
thawed swiftly to prevent precipitation and diluted in TUC buffer. Cells were treated by 
cya A while in D-MEM medium containing 100x diluted TUC buffer. To ensure similar 
conditions control cells were treated with 100x diluted TUC as well.  
Length of incubation as well as concentration of Cya A is indicated in particular 
experiment. 
3.2.10 Confocal microscopy of living cells 
Cells were plated on 36mm glass bottom dish in minimal volume one day before 
transfection. Transfection procedure was performed as described in 1.7.9.3 with scaling 
according to surface covered by cells (8cm2). For transfection approximately equimolar 
mixture of PDE8A1(WT)-mCit and PDE8A(N-WT)-mStraw was used. Medium was 
exchange 8 hours after transfection and cell culture was screened for cells expressing 
fluorescent. 
Cells were imaged on Leica TCS SP2 confocal microscope while maintaining stable 5%CO2 




3.2.11 Flow cytometry  
Flow cytometer was calibrated for the cell line used before every experiment. Scaters 
were adjusted to detected at least 95% of all events thus providing good resolution. FSC 
scaling area was adjusted.   
Viability of cells was evaluated by flow cytometry. Cells stained positive for DAPI, or EtBr 




Fig 3.4. Gating strategy as used for 
evaluation of viability of CHO cells. A- 
fluorescence of DAPI at Y xais, FSC-A on x 
axis, depicted gate marks living cells; B- 
fluorescence of DY-647 (Annexin V) on y 
axis and FSC-A on X-axis; gate marks non 
apoptotic cells C-Fluorescence of YFP on Y-







Membrane biology is one of the most prominent research interests in the laboratory of 
immunology, where this diploma thesis has been elaborated. On the basis of 
bioinformatical search PDE8A1 was identified as one protein with putative membrane 
localization similar to Src kinases associated with lipid rafts that were under investigation 
by our group (Falteisek 2008). In addition there was evidence that PDE8A plays role in 
activated T-lymphocytes (Glavas et al 2001) so decision to continue research on PDE8A 
was taken (Falteisek 2008).   
First step was to obtain full-length PDE8A coding sequence.  
 
 
4.1 Construction of PDE8A-mCit and its variants with modified N-
terminus 
Due to the research previously conducted in our laboratory (Falteisek 2008) DNA-
constructs containing PDE8A1 coding sequence were already available. However detailed 
sequencing revealed that none of the clones contained sequence identical to the 
canonical PDE8A1 (GI:47132535). The content of available clones was examined in detail 
subsequently strategy to obtain PDE8A1 coding sequence was built.  
 
4.1.1 Alternative splicing of PDE8A  
Gene organization of PDE8A has been reported and exon/intron boundaries are known 
(Wang et al 2001). Brief sequencing of three most prospective of available clones 
suggested that they carried cDNA of alternatively splice PDE8A transcripts. Analysis of 
exon composition of the clones concerned revealed that they were indeed splice variants 
of PDE8A transcript (Tab 4.1). In addition to exon 8, that is not present also in PDE8A1 
isoform, exons 3,4 and 5 were missing in the PDE8A_c1_2010. In contrast, all the exons, 
that PDE8A1 consists of, were present in PDE8A_D_tupo, however there was additional 
segment between exon 3 and 4. Similarly PDE8A_c8_2010 contained additional sequence 
region between exons 18 and 19, however lacked exons 4, 5, 7 and 9 that are present in 
PDE8A1.  The additional sequence segments found fit well on already known exon-intron 
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boundaries. Newly identified segments were found in known retained introns of PDE8A 
protein coding transcripts, however in introns they were surrounded by sequences 
different to those we have found in our clones. This indicates existence of yet unknown 
splicing sites on borders of the newly identified segments. 
 
 
1 2 3 N 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 N 19 20 21 22 23 
PDE8A_c1_2010 x x - - - - x x - x x x x x x x x x x - x x x x x 
                          PDE8A_c8_2010 x x x - - - x - - - X x x x x x x x x ! x x x x x 
                          PDE8A_D_tupo x x x ! x x x x - x x x x x x x x x x - x x x x x 
 
4.1.2 1st mutagenesis 
Cloning of PDE8A has been proven complicated (Falteisek 2008, Fisher et al 1998). 
However since constructs with incomplete or mutated PDE8A were already available 
another way to obtain PDE8A1 coding sequence was to either combine them or to repair 
the mutations present there by site directed mutagenesis, so that the resulting sequence 
would match canonical PDE8A1 (GI:47132535). 
Construct PDE8A_mCit_D, already present at our laboratory (heritage from Lukáš 
Falteisek), contained coding sequence for whole PDE8A1 protein tagged with citrine, 
however it carried point mutations 324A->G, 346G->C, 348C->T and 358T->C. Although 
mutation of A to G at position 324 would not change amino acid in resulting protein, the 
mutation of G to T at 346 in concert with mutation C to T at 348 would change valine at 
position 116 to phenylalanine. Moreover mutation of T to C at 358 would result in 
replacement of original Phe120 by leucine. Mutation of nucleotides and their 
consequences are depicted in table 4.2  
  
 
Tab 4.1 Exon composition of selected clones. Numbers (1-23) indicate recognized exons; N 
indicates segments not listed nor numbered as exon in Ensembl database;  Absence of exon is 
marked as – and its presence as X. Segments previously identified as introns are indicated with !; 




Change in nucleotide 
sequence 
Cosequences in AA 
sequence 








Otherwise PDE8A_mCit_D was considered to be complete and correct. Primer 
8a_opr_I was designed to repair above mentioned mutations, and together with primer 
PDE8A amAFP N3 R was used to perform PCR (see chapter … and the amplified segment 
was cloned into pGEM-T easy vector according to protocol provided by manufacturer.  
The resulting ligation mixture was used to transform TOP-10 chemocompetent E. coli cells 
and screened for successful ligation the next day. The result of this procedure was DNA 
construct termed PDE8A_oprI8-pGEM which contained segment of PDE8a (nt 324-2487) 
without mutations 324A->G, 346G->T, 348 C->T and 358T->C.  
The only was how to incorporate the repaired segment back into PDE8A1 coding 
sequence was through the BsrGI site however this was disrupted in PDE8a_mCit_D. 
Furthermore in PDE8A1 sequence there was another BsrGI restriction at nt 1857, splitting 
the assembly of PDE8A1 into more steps. So it was necessary to assemble PDE8A1 coding 
sequence piece by piece. The next step was to transfer nt 1857-2487 into 
PDE8A_c8_2010, that was planned to be followed by addition of segment between two 
BsrGI sites (nt 324-1857) and subsequently by addition of 5’portion of the gene that 
encoded the very N-terminus. The first step was successful indeed and resulted in 
construct PDE8A_oprI8_R14. However meanwhile the first step was finished, sequence of 
the 1534bp long segment between two BsrGI sties was determined and revealed another 
five point mutations that were present both in the template PDE8a_mCit_D as well as in 
PDE8a_opr-I8. One of those mutations, 806A->G, would eventually result in altered 
protein sequence, where lysine would be replaced by arginine (269K->R).  
  
Tab 4.2 Overview of mutations in coding sequence of PDE8A1 as 
present in PDE8A_mCit_D and their consequences in amino acid 









Fig3.1 Schematic depiction of important features of PDE8A constructs. Depicted are point 
mutations (PM) as well as restriction sites important for cloning of PDE8A1 (SacII, BsrGI 
and BamHI); A-PDE8A_mCit_D construct with primers used for site-directed mutagenesis: 
8a_oprI and 8a mAFP N3; B-PDE8A_oprI8-pGem with cloned product from mutagenic 
PCR; C-PDE8A_c8_2010 that was used as a donor of nt 135-323 segment; D- 
PDE8A_oprI8_R14 was generated by cloning of BsrGI-BamHI fragment into 
PDE8A_c8_2010; E-Hypothetical result of the next step - incorporation of BsrGI-BsrGI 
fragment into PDE8A_oprI8_R14 
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4.1.3 2nd mutagenesis 
Primer 8a_opr_II was designed to repair point mutation at A806G and covered also 
NsiI restriction site at nt 835. Then in combination with 8a_opr_I it was used to perform 
2nd mutagenic PCR (for details see methods).  Amplified segment was cloned into p-GEM 
T-easy vector system and transferred into bacteria. Isolated strain produced PDE8a_H2 
plasmid that proved to be without amino acid changing mutation in PDE8a gene. 
Segment between SacII and BsrGI from PDE8a_opr-I8_R14 (nt 135-323) was 
transferred into PDE8a_H2, yielding construct PDE8a_H2Rb-pGEM. Primer 8a_opr_II 
include Nsi restriction site that in concert with NsiI site found in multiple cloning site of 
pGem allowed the transfer of nt (835-2487) from PDE8a_oprI8-pGEM into cloned into 
PDE8a_H2Rb-pGEM resulting in construct PDE8a_H2Rb1.  
Prepared construct PDE8a_H2Rb1 contained PDE8A1 coding sequence from 2nd SacII 
restriction site (at 135th nt) till the end of the coding sequence and was important 
intermediate for generation of N-terminal variants as well as for catalytically inactivated 
PDE8A1.  




Fig. 4.2 Schematic depiction of 
important features of PDE8A 
constructs. Depicted are point 
mutations (PM) as well as 
restriction sites important for 
cloning of PDE8A1 (SacII, BsrGI 
and BamHI) and primers 
8a_oprI and 8a_oprII. A-
PDE8A_mCit_D as a template 
for site directed mutagenesis; 
B- PDE8a_H2 containg product 
of 2
nd
 mutagenic PRC indicated 
multiple cloning sites (MCS; 
purple); C- PDE8A_H2Rb 
resulted from addition of 
nt135-323(denoted as izo8) 
from PDE8A_c8_2010  to 
PDE8A; D- PDE8a_H2Rb1 was 
derived from PDE8A_H2Rb by 




4.1.4 Construction of N-terminal variants 
After construction of PDE8a_H2Rb1 the next step was to transfer the whole repaired 
construction from pGEM into mCit plasmid background. This was done by cloning 
segment between SacII and BamHI (nt 135-2487) from PDE8a_H2Rb1 into PDE8A(N-WT)-
mCit which contained PDE8a coding sequence from start codon to the second SacII 
restriction site (nt 1-135). However SacII was cutting the DNA in two places (at nt 63 and 
135) close by each other and the piece between the two restriction sites was lost during 
cloning. Once the big construct from H2Rb1 was safely in mCit vector (plasmid 
PDE8a_H2Rb16R) the short piece from in between SacII restriction sites (nt 64-135) was 
put back by another cloning step resulting in the PDE8a_H2Rb16Rb. In PDE8a_H2Rb16Rb 
the whole coding sequence of PDE8A1 was assembled a further on the construct was 





Since constructs coding for N-terminal segments of PDE8A with altered acylation 
pattern were already prepared in previous work (tab. 4.3), to construct full-length PDE8A 
localization variants it was needed to transfer each of thethis constructs (nt 1-64) into 
PDE8A(WT)-mCit. This procedure included cloning of the corresponding segments into 
PDE8A(WT)-mCit via XhoI and SacII restriction enzymes. Segment between the SacII sites 
Fig. 4.4 Construct PDE8A(WT)-mCit. 
Depicted are point mutations (PM), 
sites recognized by restriction enzymes 
and origins of particular segments. N-
segment coding for N-terminal 
fragment of PDE8A1 protein (orange) 
comes from PDE8A(N-WT)-mCit; SS-
segment (blue) is localized between the 
two SacII restriction  sites, segment was 
lost during transfer of PDE8A1 (nt 135-
2487) into PDE8A(N-WT)-mCit and was 
added back; izo_8 segment (pale green) 
comes from PDE8A_c8_2010;  H2 
segment (bright green) is the cloned 
product of 2
nd
 mutagenic PCR and 
opr_I8 segment (dark green) comes 
from PDE8A_oprI8-pGem; The 
remaining features depicted on the 
plasmids feature of the vector. For 
details see chapter “vectors”. 
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(nt 64-135) was lost during the cloning and was put back subsequently by another cloning 
step.  
construct designation postranslational modification mutation in protein 
sequence 
PDE8A(N-WT)-mCit N-myristoylation; palmytoylation - 
PDE8A(N-M)-mCit N-myristoylation C3S 
PDE8A(N-P)-mCit palmytoylation G2A 
PDE8A(N-0)-mCit none G2A, C3S 
 
. 
By assembling of PDE8A1(WT)-mCit and its acylation variants first phase of this 
diploma thesis was finished successfully and first of the goals was achieved. 
4.1.5 Preparation of catalytically inactivated PDE8a 
Cells expressing PDE8a-mCit, were often observed as losing adherence and never 
survived in culture for longer time – over two days. In case of Raw264 cells, there were 
hardly any PDE8a expressing cells observed after less than 24 hours. When compared the 
transfection efficiency of PDE8a-mCit was twice as low as that of its corresponding 
PDE8a_N-mCit constructs and the expression level differed in orders of magnitude as was 
obvious from data obtained from flow cytometry.  
The observed phenomenon raised the question whether this was due to the size 
difference between transfected constructs, or due to the cAMP hydrolyzing activity of 
PDE8a. In order to determine the cause of it, we have decided to produce catalytically 
inactivated PDE8a. Construction of catalytically inactivated PDE4d5s and 3D has been 
published previously and was based on mutation of Asp556 to alanine at that position 
(Perry et al 2002). Based on sequence alignment PDE8A and PDE4D residue 
corresponding to Asp556 in PDE4D was identified as Asp726 in PDE8A.  Comparison of 3D 
structures of PDE4D and PDE8A available in the MMDB database, further confirmed that 
Asp726 of PDE8A is in position crucial for catalysis and is part of metal binding pocket (Fig. 
4.4).  
Tab. 4.3 List of constructs coding for N-terminal fragment of PDE8A1 with putative 
posttranslational modification. Mutation that cause the altered acylation of PDE8A1 














Construct coding for catalytically inactivated PDE8A1 has been prepared by site 
directed mutagenesis (see methods) and determination of the coding sequence 
confirmed that produced protein should indeed be inactive. However it biological activity 
was not yet examined.  
4.1.6 Construction of PDE8A(N-WT)-mStraw 
In order to compare localization of full-length PDE8A1 with its N-terminal fragment, 
the citrine coding region in construct PDE8A(N-WT)-mCit was replaced by sequence 
coding for strawberry fluorescent protein yielding construct PDE8A(N-WT)-mStraw. This 
construct was crucial for simultaneous observation of expressed N-terminal fragment as 
well as full-length PDE8A1 that might provide information about factors that determine 
distribution of PDE8A1 in living cells. 
  
  
Fig. 4.4 The 3D structures of catalytic domain PDE8A (on 
the left; MMDB id 68150) and PDE4D (right; MMDB id 
94628). Asp 726 of PDE8A and Asp 556 of PDE4D are 
colored yellow and within the catalytic pocket occupy the 
same position. Structures were visualized by CN3D 
software (NCBI), displayed are residues within the range 14 
angstroms from the marked aspartate  
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4.2 Localization of PDE8A1 in relation to acylation of its N-terminus 
4.2.1 Raw264.7 
To examine localization pattern of different acylation variants of PDE8a prepared DNA 
constructs were transfected into RAW264.7 cells and their localization in relation to 












plasmatic membrane, vesicles  
PDE8A(M)-mCit N-myristoylation perinuclear membranes  
PDE8A(N-M)-mCit N-myristoylation perinuclear membranes, cytosol 
PDE8A(P)-mCit palmytoylation cytosolic  
PDE8A(N-P)-mCit palmytoylation cytosolic  
PDE8A(0)-mCit none cytosolic  
PDE8A(0)-mCit none cytosolic  






Fig. 4.5 Localization of PDE8A constructs in Raw264.7 cells (on the next page) Raw cells were 
transfected with PDE8A(WT)-mCit PDE8A(N-WT)-mCit PDE8A(M)-mCit PDE8A(N-M)-mCit PDE8A(P)-
mCit PDE8A(N-P)-mCit PDE8A(0)-mCit PDE8A(0)-mCit. Cells were stained with mitotracker red; 
transferin -AF594 and Phalloidin-AF594 as described in methods. Imagined by Olympus XI-81 























































































































4.2.2 CHO cd11 
Distribution of full-length PDE8A constructs within CHO cd11 cells was examined. The 
results correspond well with the distribution in Raw264.7 cells. However in CHO cd11 



















Fig. 4.6 CHO cd11 cells transfected with: A-PDE8A(WT)-mCit; B-  PDE8A(M)-mCit; C- PDE8A(P)-
mCit D- PDE8A(0)-mCit; Olympus XI-81 Cell’R‘ microscopic system 60X objective  
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4.2.3 Contransfection of PDE8A(N-WT)-mStraw with PDE8A(WT)-mCit and 
confocal microscopy in living cells 
To examine whether there are additional factors that determine subcellular 
localization of PDE8A1 apart from the its acylation at the N-terminus, CHO cd11 cells were 
transfected by a approximately equimolar mixture of PDE8A(N-WT)-mStraw with 





Fig. 4.6 CHO cd11 cells transfected with both PDE8A(WT)-mCit and PDE8A(WT)-
mStraw; On the very left cell transfected only by mStraw is depicted, the rest of the 







4.3 PDE8A1 vs CyaA: Examining the rivalry in living cells 
4.3.1 Toxic effect of PDE8A1-mCit  
During microscopic studies we have noted that cells expressing full-length catalytically 
active PDE8a vanished quickly from the culture. We have concluded that presence of high 
amount of PDE8a is toxic to cells expressing it and confirmed this first with RAW264.7 
cells (obviously the most sensitive cell line from tested). Major decrease of cells 
expressing full/length PDE8a in proportion to non-transfected ones was observed 
between 12th and 24th hours after transfection. This toxic effect was abolished in 
truncated N-terminal variants (Fig. 4.7).  
 
In the other cell line tested, CHO cd11, the majority cells expressing PDE8a1 was 
floating in the medium already 16 hours after transfection. Under optimal conditions CHO 
cd11 cells are adherent, thus their inability to adhere can be considered a sign of the 










































Fig. 4.8s Proportion of RAW 264.7 
expressing mCit as a result of 
transfection by: PDE8A(WT)-mCit, 
PDE8A(N-WT)-mCit, PDE8A(M)-
mCit, PDE8A(N-M)-mCit after 12 and 
24 hours. Note the decrease of cells 
expressing full-length PDE8A-mCit 
and increase of cells expressing 
PDE8A N-terminal constructs. Data 
shown comes from single 
preliminary experiment. All cell 
counts were determined by BD-LSRII 
















We have decided to investigate this phenomenon in better detail and challenge the 
PDE8A1 expressing cells with cyclase toxin of Bordetella pertussis. The reasoning behind 
the involvement of the CyA toxin into the experimental setup is as follows: 
4.3.2 The design of the experimental system 
Bordetella pertussis is known to express several bioactive proteins including toxin with 
adenylyl cyclase activity that translocate it´s cyclase domain into cytosol of target cells 
and accumulate in lipid rafts (Bumba et al 2010). PDE8a was predicted to be part of 
membrane RAFT-like microdomains due to its N-terminal double-acylation (Falteisek 
2008).   
We decided to test the hypothesis. For this design of the procedure, protein-protein 
targeting interaction of PDE8a and other proteins have been considered negligible in cells 
expressing PDE8A as result of transfection. Protein-protein targeting interactions of Cya A 
have been also considered of less importance. Based solely on shared preferences for 
lipid environment PDE8A and CyA should be colocalized in similar/identical type of 
membrane microdomains and therefore functionally interfere. If such a co-localization 
really occurs there should potentially be a concentration of PDE8a and cyaA high enough 
enabling two enzymes to compensate for their catalytic and thus toxic resulting in 
lowered toxicity for both of the “rivaling” enzymes in the cell. Cell in which the “balance 
Fig 4.9 A- Cells not transfected or transfected by PDE8A(WT)-mCit as found in either supernatant (floating) or on 
cultivation surface (adherent); B- Count of CHO cd 11 cells expresing  PDE8A(WT)-mCit adherent or floating; A,B 
cell counts were evaluated 16 hours after transfection; harvested cells were centrifuged and resupsended in the 
same volume of PBS so that the counts from supernatant and cultivation would be proportional; data shown 
comes from three parallel experiments; Error bars indicate the standard deviation. All cell counts were 















































of enzymatic power” will be achieved should be more viable, since cells that do not 
express any PDE8A should be intoxicated by Cya A and those expressing too much PDE8A 
will die in result of PDE8A expression 
Since the beginning we were aware, that all these assumptions may be incorrect. 
However we were still interested in what would happen, shall the concerned enzymes 
meet (face to face) in one cell.  
 Originally we intended to FACSort out PDE8A1-mCit expressing cells and measure 
cAMP concentration in cells after challenge of cya A. Measuring concentration in this way 
would require excessive amount of cells for analysis, however due to low transfection 
efficiencies of full length PDE8a constructs in relevant cell types (RAW, CHO CD11) this 
would subsequently require enormous cultivation surfaces and amounts of DNA, so this 
alternative was not considered as favorable. Moreover, interpretation of measured cAMP 
concentration would be very complicated, since it will not directly refer to the cell 
viability or physiological status in context of PDE8A. Due to this reasons we have banned 
this experimental procedure.  
As was already mentioned above, we decided to test the hypothesis, whether the 
balance of power between PDE8A and Cya A could be achieved and is of physiological 
relevance in transfected cells with the outcome - beneficial effect on viability of PDE8A 
expressing cells (in the context of Cya A and vice versa). We have finally decided to 
challenge PDE8a-mCit expressing cell with CyA in mixed culture of transfected and non-
transfected cell and analyze the complex cell suspension using FACS analysis. Measuring 
the mixed culture would provide information about viability of PDE8A-mCit expressing 
cells in relation to the viability of non-transfected ones in the complex system with the 
toxin involved.  Important advantage of this setup is that the fluorescence signal in the 
transfected cell is proportional to the amount of PDE8A itself – and could be 
quantitatively correlated to the potential functional effect on the cell survival using 
particular concentration of the Cya A toxin.   
4.3.3 Proportion of PDE8A1(WT)-mCit but not PDE8A1(N-WT) expressing cells 
is increased after challenge by cya A 
CHO cd11 cells transfected by either PDE8A1(WT)-mCit or PDE8A1(N-WT)-mCit have 
been challenged by different concentration of cya A 12 hours after transfection. 
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Examined were 3 different concentrations of 1, 5 and 45 ng of toxin in 500µl of medium 
per 1/24-well plate corresponding to 1.9 cm2 cultivation surface. Then, 20 hours after 
addition of toxin. Proportion of cells expressing the fluorescent tag within the surviving 
population was evaluated by flow cytometry (Fig. 4.10). Challenge of sample by cya A 
caused enrichment of PDE8A1(WT)-mCit expressing cells in the population of living cells. 
In cells, not treated with cya A, 15.6% of cell expressed PDE8A1(WT)-mCit, while this 
proportion has risen to 22.9, 21.6 and 22.0 when 1, 5 or 45 ng of cya A were used 
respectively. In contrast proportion of PDE8A1(N-WT)-mCit was decreasing in response to 




4.3.4 Acylation pattern of PDE8A1 determines its interplay with cya A 
Preliminary data collected showed that expression of PDE8A1(WT) may have some 
protecting effect, in case of Cya A challenge. It has been verified that modified acylation 
pattern of PDE8A1 variant directed produced proteins into different cellular 
compartments (chapter xxx). Cellular localization pattern of PDE8A1 could therefore play 
crucial role upon treatment by Cya A. To test whether localization of PDE8A1 matters in 
Cya A intoxication, CHO cd 11 cells were transfected with the PDE8A1-mCit constructs 
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encoding variants with the different acylation motif (double-acylated, myritoylated only, 
palmitoylated only, without acylation) . Twenty hours after transfection cells were 
challenged by incubation with 200ng Cya A in 200µl of DMEM medium for 3 hours and 
analyzed subsequently. 
For determination of cell viability we used in parralel combination of DAPI and FSC  and 
staining by annexin V combined with FSC.  
 
Quantitation of the toxicity (using DAPI) yielded the following results:  
When untreated, 11.2% of living cells expressed PDE8A1(WT)-mCit, however after 
treatment by cya A it was 18.6% of the living cells that expressed PDE8A1(WT)-mCit. 
Similarly, 12.3 % of living cells expressed PDE8A1(M)-mCit, but after treatment by Cya A 
this number has reached 18.6%. Proportion of cells expressing PDE8A1(P)-mCit or 
PDE8A1(O)-mCit was not increased after Cya A challenge.  
Staining by annexin V distinguishes apoptotic from non-apoptotic cell. In the 
population of non-apoptotic cells, increase from 15.8% to 18.0%  of PDE8A1(WT)-mCit 
was observed after treatment with Cya A. Again (similarly to PDE8A1(WT)-mCit) increase 
from 15.7% to 20.4% in the case of myristoylated form PDE8A1(M)-mCit was observed. 
Proportion of other two variants has decreased upon challenge by Cya A – indicating the 
lack of the Cya A mediated protection and induction of the Cya A mediated cytotoxicity.   
In summary, proportion of PDE8A1 expressing cells has been increased upon Cya A 
challenge in the case of PDE8A1(WT)-mCti and PDE8A1(M)-mCit (both exhibiting 
membrane localization) however remained constant (or decreased) in the case of other 







Fig.4.11: Proportion of PDE8A1-mCit expressing cells (acylation variant indicated at X-axis) in 
population of living cells as determined by flow cytometry. Left (A) living cells were 
determined by FSC and dapi staining; Right (B) Non-apoptotic cells as determined by Annexin 






































































5.1 Alternative splicing and construction of PDE8A1-mCit variants 
In thesis presented here, preparation of fluorescently labeled PDE8A1 constructs with 
altered acylation variant is reported. Several problems were encountered during 
construction of full-length PDE8A1-mCit encoding plasmid.  
First it was impossible to amplify 5’ terminal region of the coding sequence from cDNA 
libraries by PCR experienced within the frame of previous work with PDE8A1 conducted in 
our laboratory (Falteisek 2008). A similar problem occurred during the first cloning and 
characterization of human PDE8A, where authors state that, despite their extensive effort 
they were not capable of PCR amplification of longer PDE8A sequence than they actually 
report although they predict its existence (Fisher et al 1998). Detailed examination of 
PDE8A gene organization revealed high CG content around the 5’ terminal region of the 
ORF that might be the cause resistance of this region to PCR amplification (Wang et al 
2001, Glavas et al 2001).  
Second problem restraining the cloning of PDE8A1 was alternative splicing. There were 
several clones of PDE8A with different exon composition. Alternative splicing is a 
common trait among PDE genes (see chapter X.Y, Conti and Beavo 2007) and it has 
already been reported (Wang et al 2001). However there are very few studies that would 
focus on addressing the alternative splicing of PDE8A. The one available is concerned with 
PDE8A transcripts found only in testis and CD4+ lymphocytes, yet there are more tissues, 
where PDE8A transcripts are present, such as spleen or colon (Wang et al 2001). Thus 
alternative splicing of PDE8A has not been assessed in detail so far. In this study new 
splice variants and putative novel exons are reported. The exon/intron boundaries 
correspond well with those already known and the novel putative exons reported are 
found within the region of PDE8A gene. Sequences neighboring the novel segments in the 
clones are found separated from them in genome sequence, thus suggesting that they are 
exons indeed. 
The last problem was that all the clones generated at the beginning of PDE8A project 
(during several rounds of preparation) differed in DNA sequence from sequence reported 
as canonical (GI:47132535) altering amino acid sequence in translated protein. After 
Although the resulting amino acid substitutions are not localized in regions with reported 
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function (uniprot entry O60658 - PDE8A_HUMAN), we considered to be on a safe side 
avoiding unpredictable consequence that might be hard to recognize retrospectively. 
Thus we decided to eliminate mutations.  
Considering the available collection of clones and the troubles that de novo cloning of 
PDE8A has brought to others, it seemed that combining and repairing the available clones 
may be easier way to obtain PDE8A1 canonical coding sequence. Although additional 
point mutations to be corrected were generated and discovered during the procedure, 
finally time-consuming effort lead to the desired goal and PDE8A1 tagged with citrine on 
its C-terminus was obtained.  
5.2 Catalytically inactive PDE8A1 
For further experiments with PDE8A1 in mammalian cells its catalytically inactive 
variant represents an important control. Although biological activity of protein encoded 
by the prepared construct has not been assessed, recently another unrelated group 
prepared D726A PDE8A1 and considered it catalytically dead (Brown et al 2012). 
Although, no direct proof has been published yet and only indirect indications are 
available, it is most probable that D726A PDE8A1 lacks cAMP hydrolyzing activity. Most 
likely, although independent, both preparations of catalytically inactive PDE8A1 use the 
same substantiation.  
5.3 Localization of PDE8A1 
Localization of PDE8A1 was examined in Raw264.7 and to lesser extent also in CHO 
cells. Observation confirmed previous notion of Lukáš Falteisek that distribution of 
PDE8A1 is determined by both N-myristoylation (Gly2) and palmitoylation of Cys3 
(Falteisek 2008). Although posttranslational modification such as phosphorylation sites, 
N-myristoylation and amidation have been predicted for PDE8A (Wang et al 2001, 
Gamanuma et al 2003) none of them has been experimentally confirmed until recently 
(Brown et al 2012). The only known posttranslational modification is phosphorylation of 
by PKA at serine 359 that activates the PDE8A catalytic activity (Brown et al 2012).  
Moreover parallel observation of PDE8A(N-WT)-mStraw with PDE8A(WT)-mCit 
suggested slightly different localization of N-terminal fragment in comparison to full-
length constructs. This indicates that some other factor, such as interaction domain PAS 
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identified in PDE8A1 (Soderling et al 1998, Wang et al 2001, Wu et al 2004), may play 
important role in directing localization of PDE8A. 
Here provided evidence for the first time demonstrates that both N-myristoylation as 
well as N-palmytoylation alters the distribution of full length PDE8A1 within the cell. 
 
5.4 PDE8A1 and cya A 
Experimental system to address biological interaction of PDE8A1 and cya A was 
designed. It should be noted that environment in which the interaction was tested is 
rather artificial for both proteins. First of all expression levels of PDE8A1 are unusually 
high in this system. Moreover CHO cells are adherent cell line with epithelial morphology 
derived from Chinese hamster ovaries, while target cells for cya A are mostly phagocytic 
cells of immune system. On the other in this way not the fine tuning but the robustness of 
the cAMP system is addressed.  
Observed was modest increase in viability of PDE8A(WT)-mCit and PDE8A(M)-mCit 
transfectants upon challenge by cya A. Both of the produced proteins shared membrane 
localization although PDE8A(M)-mCit preferred endomembrane structures, most 
probably endoplasmatic reticulum (Falteisek 2008) over the cytoplasmic membrane and 
PDE8A(WT)-mCit was found almost exclusively on cytoplasmic membrane. There was 
basically no difference in viability of other two constructs whether the toxin was added or 
not.  
There are several possible reasons for this observation. First is the activity of proteins 
with different localization that might be different and differently regulated. Activity of 
PDE8A1 is increased by interaction with β-arrestin or PKA (Wu et al 2004, Brown et al 
2012) this activation might not be possible for soluble mutant protein. Moreover N-
terminal fragment of PDE8A1 is important for the regulation of its activity (Wang et al 
2008) and non-acylated N-terminus may prefer conformation not suitable for catalytic 
activity. Moreover the soluble variants may be undergoing degradation or be otherwise 
restricted in activity. Other possible explanation is that cytosolic PDE8A1 mutants are fully 
active and it is indeed due to the different localization  
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Provided data are considered preliminary and before driving definitive conclusions 
additional properties of PDE8A1 have to be evaluated otherwise the interpretation of this 






Construction of PDE8A1 
 Fluorescently tagged full length PDE8A1 was successfully constructed ( 
PDE8A1(WT)-mCit ) 
 Three localization variants of PDE8A1 were prepared, namely:  
o PDE8A(M)-mCit (coding for N-myristoylated protein) 
o PDE8A(P)-mCit (coding for palmytoylation at Cys3) 
o PDE8A(0)-mCit (coding for non-acylated protein) 
 Construct coding for catalytically inactivated PDE8A1 was prepared 
 Construct PDE8A(N-WT)-mStraw coding for N-terminal fragment of PDE8A1 
tagged with mStrawberry fluorescent protein suitable for study of 
colocalization of full-length PDE8A1 and its N-terminal fragment 
Localization of PDE8A1 
 Double acylated full length PDE8A1 (PDE8A(M)-mCit) was found to localize to 
cytoplasmic membrane of both Raw264.7 and CHO cd11 cells 
 Myristoylated  full length PDE8A1 (PDE8A(M)-mCit) was found to localize to 
perinuclear membran of both Raw264.7 and CHO cd11 cells. Additionally it was 
found to diffuse freely in the cytosol of Raw264.7 
 Mutant proteins that lacked myristoylation (PDE8A(P)-mCit and PDE8A(0)-mCit) 
diffused freely in the cytoplasm 
 Full length PDE8A1 with double acylation exhibited slightly different 
distribution than the corresponding N-fragment 
Cytotoxicity of PDE8A1 and Cya A 
 Expression of full length PDE8A1 (duble acylated –WT and myristoylated – M) 
was found toxic, while expression of corresponding N fragments was not 
 Full-length PDE8A1 with membrane localization (duble acylated –WT and 
myristoylated – M) provided modest protection from intoxication by Cya A for 
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